Core response above - further details below:

In May this year, Active Watchful Waiting lodged a complaint with the Australian Health Practitioner Regulation Agency about the public website of Kaleido Health Centre, the LGBTQ+ health service operated by ACON Health Centre Limited in Surry Hills.

Our complaint was narrow and deliberately so. It was not about what happens inside Kaleido’s consulting rooms. It was not about whether gender-affirming care works. It was about a website - the pages a parent reads at eleven o’clock at night, before they have spoken to anybody, when they are deciding whether to make an appointment for their child.

Those pages advertise GP-led hormone therapy, social transition support and surgery referrals. They describe the care as ‘safe’, ‘high-quality’, ‘best-practice’, ‘evidence-based’ and ‘developmentally appropriate. They confirm - on a page that had been removed from the site’s navigation menu - that services are available to people under 18.

What they do not contain, anywhere, is a single word about risk. Not blood clots. Not bone density. Not fertility. Not the fact that some effects don’t reverse when you stop. Not the existence of any alternative pathway. We audited every publicly accessible page. The count of disclosed material risks was zero.

On 16 July, AHPRA wrote back. The letter runs to a page and a half. It closes the matter.

Read the letterhead

The most revealing thing about the response isn’t in the reasoning. It’s in the signature block.

The letter is signed by the Criminal Offences Unit, National Legal Services. Replies are directed to

criminal.offences@ahpra.gov.au

.

I am assuming this matters more than it might appear. Section 133 of the Health Practitioner Regulation National Law - the advertising provision - is an offence provision. Breaching it is a prosecutable act carrying a penalty. So when a complaint about advertising lands at AHPRA, it lands with the unit that decides whether to prosecute (I assume).

And the question a prosecution unit asks is not - (I am thinking) - “is this website compliant?” It is not “should this be fixed?” It is closer to: would we run this to a criminal standard of proof, in a court, against a defendant with lawyers?

I think those are very different questions, and they produce very different answers. A case built on what a website leaves out - on the total impression created across seven pages read together, where every individual sentence is technically defensible - is close to the last thing a prosecutor would take on. It requires a court to infer a false impression from absence. Would a prosecutor build a case out of absence if they can help it?

If so, this means the letter we received is not a finding that Kaleido’s advertising is compliant. It is a decision not to prosecute. AHPRA has not said the website is fine. It has said it will not lay charges. In the public conversation that follows, that distinction is going to matter and it will be blurred constantly.

The four reasons, and the two questions nobody asked

Portion of the AHPRA Letter in response to our Kaleido Health Centre audits found at

https://www.aww.org.au/informed-consent

AHPRA gave four reasons for finding no breach. Two of them answered questions we did not put to them.

“It does not make claims that any particular treatments are risk-free, universally effective, or appropriate for all patients.”

Correct. We never said it did. The complaint was not that Kaleido made a false statement. It was that Kaleido misled by omission - a distinct and expressly recognised category. AHPRA’s own advertising guidelines say advertising may be misleading when it “misleads, either directly or by implication through the use of emphasis, comparison, contrast or omission,” and when it “provides partial information and/or omits important details.” The guidelines instruct advertisers to look at the overall impression, and to consider who the audience is and what the advertising is likely to mean to them.

AHPRA’s response suggests they never applied that test. They applied a narrower test - did Kaleido say something false? -ignored Finding 10 decided the answer was no, and stopped.

“References to alignment with AusPATH Standards of Care are not misleading in the context presented, noting that these standards are recognised as an Accepted Clinical Resource by the Royal Australian College of General Practitioners (RACGP).”

Also an answer to a different question. We did not argue that citing AusPATH was illegitimate. We argued that Kaleido claims alignment with AusPATH while omitting the very things AusPATH’s own documentation contains. AusPATH’s consent forms list stroke, blood clots, liver damage, reduced bone density, cancer risk. AusPATH requires fertility counselling before treatment begins. AusPATH tells providers it is their responsibility to know the legal requirements that apply to under-18s in their state.

Kaleido’s public materials contain none of it.

That is a question about conformity - do they do what the standard says? AHPRA answered a question about provenance - is the standard a real standard from a real body? Being listed as an Accepted Clinical Resource tells you where a document came from. It tells you nothing about whether a particular clinic follows it.

“Statements referring to ‘safe’ care are used in the context of the service environment, including cultural and psychological safety, rather than as claims about the clinical safety of any particular interventions.”

That is not a finding, but an interpretation not supported by the site’s text. It’s an available reading of the word “safe,” offered without any reasoning to support choosing it, and without reference to where on the site the word actually appears - including on a page headed “Informed, safe & high-quality care” that goes on to list hormone therapy and surgical access.

But set “safe” aside entirely, because the more serious problem is what this bullet doesn’t touch.’ Evidence-based’ cannot be re-read as cultural safety. Neither can ‘best-practice’. Neither can ‘developmentally appropriate’, which is a claim about how a treatment fits a particular group of patients - children - and nothing else. Those three phrases are untouched by the letter.

And there is a specific obligation attached to them that AHPRA never reaches. Its guidelines require advertisers to be able to substantiate effectiveness claims with acceptable evidence - meaning formal research, systematic studies, ordinarily peer-reviewed - and expressly rule out uncontrolled studies, before-and-after comparisons, self-assessment surveys and anecdotal clinical observation. The burden sits with the advertiser.

AHPRA’s letter never asks whether Kaleido holds that evidence. It moves directly to noting they didn’t over-claim. That inverts the obligation: the guideline asks what the advertiser can prove, and the response asks only whether they went too far.

Finally, one entire limb of our complaint is missing. We alleged a breach of section 133(1)(d) — creating an unreasonable expectation of beneficial treatment. It is a separate prohibition with its own test. It appears nowhere in the response. Not rejected. Not mentioned.

The sentence that actually decides it

Strip away the four bullets and one sentence is carrying the letter:

The National Law does not require advertising about the availability of a service to include detailed information about risks, side effects, eligibility criteria or alternatives for each treatment that might be provided within the service. Those matters form part of the informed consent process between a practitioner and patient.

I want to be fair about this, because it is probably a correct statement of the general position. Health services advertise availability all the time without publishing a risk register. Where AHPRA has wanted advertising-stage risk disclosure - as it does for cosmetic surgery - it has written specific rules to require it. The existence of that special regime implies the general one doesn’t carry the same duty.

So the ruling is defensible. It’s the consequence that deserves attention.

AHPRA’s position is that risk information belongs in the consulting room, between practitioner and patient. Fine. But look at what that means when you lay it beside everything else.

The consulting room is private. Nobody audits it. There is no public record of what was said, no way for a parent to check in advance what they will be told, and no external verification that the AusPATH consent form - the one with the strokes and the clots and the permanent infertility - is ever put in front of anyone.

The website is the only part of the system a family can inspect before they commit. And the regulator has now said, in writing, that the website carries no obligation to tell them anything.

But there is a second problem, and it is worse, because this part isn’t invisible at all.

AHPRA defers the disclosure obligation to “the informed consent process.” The obvious question is: which informed consent process?

Australia has a settled national definition, from the Australian Commission on Safety and Quality in Health Care. Informed consent is a person’s voluntary decision, made following the provision of accurate and relevant information about the intervention and the alternative options available, and with adequate understanding of the benefits and material risks of what is proposed. In practical guidance issued in May 2026, the Commission spelled out what those alternatives include: doing nothing; watching and waiting; lifestyle interventions.

That definition is not obscure. It appears, quoted word for word, on page 12 of the AusPATH Standards of Care - the very standards Kaleido says it aligns with, and which AHPRA has now accepted as adequate context.

On the same page, AusPATH sets out its own operational model. The threshold for starting hormone therapy is consent itself. Mental health professionals are engaged on request. The clinician’s role, the document says, is to facilitate and respect the patient’s choices. Mental health conditions - including eating disorders - are expressly excluded as contraindications.

Nowhere in the document is any alternative to hormone therapy presented. The phrases “exploratory therapy,” “watchful waiting,” and “no treatment” as a clinical option do not appear in it. Mental health support is positioned as something that runs alongside hormone therapy, not as a different road a patient might take instead.

So AusPATH quotes the legal standard at the top of the page and describes, immediately underneath it, a model that does not deliver two of the things that standard requires.

This produces a consequence that ought to trouble anyone who works in medicine. The Commission’s own principles for assessing whether a patient has legal capacity to consent require, among six matters, that the person be able to weigh up the consequences of their choices — including the choice to refuse treatment. You cannot weigh a choice you have never been shown. If no alternative has been put in front of a patient, there is nothing on the other side of the scale. That capacity requirement is not occasionally missed under the AusPATH model. It cannot be met under it, because the input it depends on was never designed in.

And the consent forms at the back of the AusPATH document, which are the ones a patient actually signs, list named physical effects but say nothing about the findings of the Cass Review, the York systematic reviews, the 2025 US Department of Health and Human Services review, the GRADE certainty ratings those reviews produced, detransition, the persistence of mental health problems after treatment, or lifelong medical dependency. The forms offer instead a single sentence: research is ongoing, and the provider will monitor.

All of this is checkable in an afternoon. Our full audit of the AusPATH standard — three findings, each one verifiable by reading the page cited - is published at

aww.org.au/audits

.

This is where AHPRA’s reasoning fails on its own terms. The regulator has not said risk information is unnecessary. It has said the website need not carry it because the consent process will. That is a deferral, and a deferral is only as good as the thing deferred to. Here it routes the family to a process that has been designed, in a published document anyone can read, to omit two of the very things the deferral assumes it supplies.

And no professional guideline can fix this by fiat. In Rogers v Whitaker, the High Court held that the medical profession does not set the standard of disclosure. A practitioner must warn of risks that a reasonable person in the patient’s position would be likely to attach significance to. Following a professional body’s model is not a defence to failing that duty. AusPATH cannot lower the bar. It can only fail to reach it - and leave every clinician who relies on it standing underneath.

Which leaves the disclosure obligation resting entirely at the one point in the process that is invisible to everybody outside the room - and resting on it at the exact moment when the family has already chosen the clinic, already made the appointment, already sat down. The decision to walk through the door is made on information the regulator says the door isn’t required to provide.

That is not a loophole somebody exploited. It’s a structural gap, and it has now been confirmed by the regulator whose job it is to mind it.

What happens next

We will be writing back to AHPRA. Not to re-argue the evidence - that isn’t the issue - but on three narrow points: that section 133(1)(d) was pleaded and never addressed; that the assessment applied only the false-statement limb of AHPRA’s own guidelines and not the omission and overall-impression limb on which the complaint was built; and that the substantiation requirement for “best-practice” and “developmentally appropriate” was never examined.

We will also ask AHPRA to confirm something simple: whether this was assessed as a decision about whether to prosecute, or as an assessment of whether the advertising complies. If it was the former - and the letterhead suggests it was - then the compliance question has not been answered at all. It has only been declined.

Copies will go to the National Health Practitioner Ombudsman, to the Health Care Complaints Commission in New South Wales, and to the RACGP - whose listing of the AusPATH standards as an Accepted Clinical Resource has now been used, by a national regulator, as a reason not to look further at a clinic that does not follow them.

The parallel complaint to the Australian Competition and Consumer Commission, under the Australian Consumer Law, is unaffected. Different statute, different test, a well-developed body of law on when silence misleads - and no provision anywhere in it that says the obligation to be truthful can be deferred to a private conversation later on.

Meanwhile there are 49 private gender clinics in Australia. We have now audited more than a third of them. Every single one has been rated seriously deficient.

We will keep going.

Catherine Anderson-Karena is Founding Director of Active Watchful Waiting Inc. The Kaleido Health Centre audit, the section 133 notification, are available at

https://www.aww.org.au/informed-consent

AHPRA’s response is available at

HERE

Or make a One-time donations ($5, $10 or $25)

In April 2025 the UK Supreme Court held that “sex” and “woman” in the Equality Act 2010 refer to biological sex - a characteristic that can be verified against observable criteria. In June 2026 the government published a draft Conversion Practices Bill that, for the first time in UK statute, gives legal content to “transgender identity.” The definition includes a person who “identifies as neither male nor female or as not solely male or female.” This limb rests solely on self-report.

Conversion Practices Draft Bill - Transgender Identity Definition

The same legal system now treats one category as objectively ascertainable and another as effectively non-falsifiable, while attaching both criminal consequences and children’s medical pathways to the latter.

On the face of it, the Bill does not readily criminalise ordinary statements of biological fact or clinical caution. Its offence requires abusive conduct, specific intention to change a person’s belief about their transgender identity, and serious harm or substantial distress affecting daily life. The difficulty lies not in the thresholds themselves but in the category the Bill chooses to protect and the domains into which it imports that category.

The new statutory definition

Until now, UK law has protected “gender reassignment” - a process - rather than a free-standing identity. The draft Bill defines “transgender identity” to include a person who is undergoing or has undergone reassignment, who is transsexual, or who identifies as neither male nor female or not solely male or female. The list is expressly non-exhaustive. The final limb is defined by the individual’s own account and has no external test by which it can be confirmed or disproved.

A definition’s primary function is to permit verification in a given case. “Adult human biological female” can be tested against physical criteria. “A person’s sense of being neither male nor female” cannot. No state of affairs external to the report could demonstrate that the description does not apply. In anti-discrimination law this feature is not disabling: the law protects religious belief and political opinion without requiring an objective test of their truth. The relevant question is whether adverse treatment occurred because of the claimed belief.

The position changes when the same category is imported into domains that requiring operational decisions — clinical pathways, consent, or criminal liability. There the absence of an external test ceases to be neutral.

Consent and the healthcare exemption

UK consent law, as stated in Montgomery v Lanarkshire Health Board[2015] UKSC 11, requires disclosure of information that a reasonable person in the patient’s position would consider material. This includes risks, alternatives, and the option of no treatment.

A pathway of social transition followed by puberty suppression and cross-sex hormones rests on the premise that the child has a transgender identity that ought to be affirmed as a settled fact. After the Cass Review (2024), that premise has a weak evidence base and no agreed diagnostic test or biomarker. Whether that premise is as robust as presented is information a reasonable parent would likely consider significant. Under Montgomery, it is therefore material.

The Bill’s healthcare exemption provides that clinical conduct is not a conversion practice unless it “falls far below the standards reasonably expected.” This test measures conduct against prevailing practice. Where prevailing practice is affirmation, the exemption protects the very approach whose evidential foundation is contested. It reinstates the “what doctors usually do” standard that Montgomery rejected in favour of what a reasonable patient needs to know.

The Minister has observed that a person cannot consent to abuse. That proposition is not in dispute. The issue is the prior duty to disclose material information about the premise on which treatment is offered.

The developmental pathway the Bill cannot reach

The Bill’s definition of conversion practice includes conduct intended to cause a person to believe they do not have a particular sexual orientation.

Picture a girl of twelve or thirteen, uneasy in her body as puberty arrives, starting to notice she is drawn to other girls, with no steady language for any of it. An explanation is available to her everywhere - from friends, from school, from the clinic: the discomfort means she is really a boy. Her self-description is treated not as something to be understood over time but as a fact to be affirmed now. Her name changes, her records change. Everyone is kind. And a possible future - growing into a lesbian woman at home in her own body - is not forbidden to her. It is simply bypassed, before she ever reaches it.

A same-sex attracted girl who comes to understand herself as a heterosexual boy has come to hold precisely that belief. The outcome falls within the statutory language.

The Bill nevertheless cannot address this pathway. It tests intention rather than effect. Adults who affirm the child’s stated gender identity intend to support that identity. The filters trigger on abuse, violence, threats and coercion. But the forces that channel this child are soft, cumulative and unlikely to look like any of those. The Bill requires serious harm now, while the harm of this pathway tends to arrive years later, as physical injury, regret, detransition or confusion about a sexuality that was never allowed to develop. Its protection orders are also safeguarding machinery pointed in one direction. Sought by police or councils and made in the family courts, they can treat a parent’s hesitation to affirm as the risk to be managed. The channelling itself, because it takes the form of affirmation, remains invisible.

The Cass Review recorded clinical concern that, for some children, a trans identity had become more readily accepted than a gay or lesbian one. Detransition studies illustrate the mechanism when it occurs. Surveys of detransitioners have recorded unprompted reports of internalised homophobia or difficulty accepting same-sex attraction as factors in transition and later detransition. The argument does not require precise prevalence data. It requires only the narrower proposition, accepted even by critics of the desistance literature, that identity in childhood is frequently unsettled and that treating it as settled can close futures that remained open.

The objection and the missing third position

The principal objection is that gender identity is innate, so affirming it protects a real trait while questioning it constitutes conversion - conduct the Bill’s other limb is intended to capture.

This response requires no general claim that gender identity does not exist or cannot be stable in adults. It requires only the narrower proposition that, in childhood, the picture is often not yet fixed. That is the proposition the objection must deny. Immutability is assumed by the affirming position rather than required by the Bill, which equally prohibits conduct intended to cause a child to acquire a transgender identity. Declining to settle the question for a child is not suppression; it is a refusal to make irreversible social and medical decisions on the child’s behalf while development remains fluid. A law that cannot distinguish between these two stances treats patience as harm.

The Bill therefore operates with only two recognised positions: suppression and affirmation-as-direction. It leaves unaddressed the third: taking the child’s distress seriously while declining to resolve the identity question prematurely. That stance keeps the widest range of futures reachable for as long as possible.

Conclusion

The legal system is simultaneously affirming that biological sex is an objective, verifiable characteristic for the purposes of the Equality Act and constructing criminal offences and clinical pathways around a category whose core element cannot be verified externally and can directly contradict that characteristic. The girl whose distress is real and whose development remains open, sits between these two positions. The Bill would protect her from coercive attempts to suppress a transgender identity. It contains no mechanism to address the institutional and clinical process that may settle her into being trans before she has had the opportunity to explore alternatives, before she has a chance to find out who she is.

Sources: Draft Conversion Practices Bill (CP 1604), Cabinet Office / Office for Equality and Opportunity, June 2026; For Women Scotland Ltd v The Scottish Ministers [2025] UKSC 16; Montgomery v Lanarkshire Health Board [2015] UKSC 11; Cass, Independent Review of Gender Identity Services for Children and Young People (2024); Littman (2021), Archives of Sexual Behavior; Vandenbussche (2022), Journal of Homosexuality; MacKinnon et al. (2023), PLOS ONE.

Ask a lesbian in her fifties what would have become of her if she had grown up now, and a striking number give the same answer: she would have transitioned. A gender-nonconforming girl, uncomfortable in herself and attracted to other girls, would have been read - and would have read herself - as a boy. It is an observation that has circulated in lesbian and gay circles for years without reaching much of the public. The detransition studies now give it an evidence base.

In Lisa Littman’s 2021 survey of 100 detransitioners, almost a quarter - 23% - described homophobia or difficulty accepting themselves as lesbian, gay, or bisexual as part of why they transitioned and later stopped. They were not asked about it. They raised it themselves. Littman’s account of that group includes people who assumed they were transgender because they had not yet understood themselves to be gay. In Elie Vandenbussche’s 2022 survey of 237 detransitioners, 52% reported a need to learn to cope with internalised homophobia. In a 2023 Canadian study in PLOS ONE - not a gender-critical source, and sympathetic to affirming care - participants described transition as a way to escape being female, and reflected that theirs may have been driven by a homosexuality they could not accept, or by autism or trauma their clinicians never explored.

The pattern is consistent. A same-sex attracted child cannot bear, understand, or accept being gay. Transition offers a way to make the conflict disappear. The girl attracted to girls becomes a straight boy; the boy attracted to boys becomes a straight girl. The attraction is not resolved through acceptance. It is dissolved by moving into a category where it no longer reads as homosexual.

No one’s orientation is changed. These young people remained same-sex attracted - which is how they came to recognise what had happened, and often why they detransitioned. What changed was not who they were attracted to but how that attraction was read: a lesbian reconstituted as a heterosexual man. The direction is the one old conversion therapy always aimed at - a gay child steered away from a gay future - reached by the opposite route. No one set out to do it. The de-homosexualising is a byproduct of affirming a cross-sex identity.

These are people who detransitioned, not a cross-section of everyone who transitions, and most who transition do not detransition. So the studies do not tell us how common this is. They tell us it is real, and not rare among those it touches. For a question about children, that is enough to matter.

What the Bill can and cannot see

The Conversion Practices Draft Bill (CP 1604, June 2026) defines a conversion practice as conduct carried out “with the intention of” changing someone’s sexual orientation or transgender identity, or their belief about either. Everything turns on those four words. It is an intention test, not an effects test.

Old-style conversion therapy meets it easily. Someone sets out to make a gay person straight; the intent is the whole point. That practice is real, it is harmful, and the Bill catches it.

The pathway the detransitioners describe does not meet it. The adults affirming a distressed girl intend to affirm her gender identity. They do not intend to change what she believes about her sexuality - even though that is the effect, and even though the Bill’s own words describe it: causing a person to believe that they do not have a particular sexual orientation. The result sits inside the definition. The intention requirement keeps it out.

Two further features seal the gap. The Bill only bites on conduct that is abusive - coercive, threatening, pressuring. Affirmation presents as the opposite: warm, validating, received as care. And clinical conduct is exempt altogether unless it falls “far below the standards reasonably expected.” Affirmation before exploration has been the standard. So the one pathway most likely to steer a gay child away from a gay future is the pathway the Bill protects - by default, and as a mark of good clinical standing.

The same filters run the other way for exploration. A therapist who helps a child sit with distress, rather than affirm a new identity, is easier to cast as trying to change a transgender identity, and easier to accuse of emotional pressure. The Bill’s words are even-handed between affirming and questioning. Its architecture is not. Affirmation passes through untouched. Exploration is the conduct left exposed.

A safeguarding question

The Bill’s own machinery points elsewhere. Its protection orders can be sought by a local authority or the police and made in the family courts, to secure a child’s health, safety and wellbeing. That is the language of safeguarding. And safeguarding asks a different question than affirmation does.

Not: was this child affirmed or questioned? But: before a cross-sex pathway was set in motion, social or medical, did anyone seriously explore what the distress was about? Same-sex attraction and shame about it. Gender-nonconformity. Trauma. Autism. Misogyny. Bullying. Family or community shame. Where that exploration does not happen, affirmation becomes a route away from a homosexual outcome - not through anyone’s cruelty, but as the default setting of a system that never asked the question.

For children, the stakes are not hypothetical. The long-standing finding is that most gender-distressed children, left alone, grow comfortable in their own bodies, and a large share grow up gay. The Cass Review found that social transition is not a neutral act, and recorded clinicians’ unease that, for some children and families, a trans identity had become easier to accept than a gay or lesbian one. Affirming that identity as the default does not settle a child’s distress about being gay. It removes the child from the category before the question is ever asked.

A conversion ban is meant to stop adults steering children away from who they are. This one is built to catch the coercive practice of the past and to wave through the affirming one of the present - the one the detransitioners keep describing. None of it requires anyone to have intended harm. It requires only that the Bill, as drafted, cannot see it, and that the children least able to speak for themselves are the ones it leaves out.

Sources: Littman (2021), Archives of Sexual Behavior; Vandenbussche (2022), Journal of Homosexuality; MacKinnon et al. (2023), PLOS ONE; Cass (2024), Independent Review of Gender Identity Services for Children and Young People; Conversion Practices Draft Bill (CP 1604), Cabinet Office, June 2026.

Today, submissions closed on New Zealand’s Legislation (Definitions of Woman and Man) Amendment Bill. Five weeks ago, Australia’s Full Federal Court handed down its final word in Giggle v Tickle. Every commentator who has written about either event has written about the same things: apps, sport, shelters, prisons, bathrooms. Nobody has yet traced what an undefined legal term does once it reaches a consent conversation for a child. That is what AWW’s submission to the New Zealand committee argues, and it is why this piece treats the two countries’ fights as one fight, not two.

The clinics already share the guidance

New Zealand and Australia are not just watching each other’s parliaments. The Australian Standards of Care and Treatment Guidelines for trans and gender diverse children and adolescents — the document AWW has audited three times over — states plainly that it was developed in consultation with professionals working across both countries. A definitional fix in either jurisdiction’s law does not stay contained to that jurisdiction’s clinics. The guidance crosses the Tasman already; the legal terrain underneath it currently does not.

That makes the comparison between the two countries’ positions on “gender identity” more than academic interest. It is the same downstream practice, fed by two separate and very differently shaped upstream arguments.

Four differences worth naming precisely

Definitional history runs in opposite directions. Australia’s Sex Discrimination Act 1984 originally defined “man” and “woman.” The 2013 amendments removed those definitions and inserted a circular definition of “gender identity” in their place — the term is defined by reference to a person’s own identification, with no external test. New Zealand has never had a statutory definition of “man,” “woman,” or “sex” in its general law at all. The Bill submissions closed on today is the first attempt to create one. Australia moved from defined to undefined. New Zealand is moving from undefined toward defined, if the Bill survives committee.

One has been tested in court; the other hasn’t been tested anywhere. New Zealand’s position rests on a Crown Law opinion delivered by the Acting Solicitor-General in 2006, in response to a question raised the previous year during debate on a member’s bill that was subsequently withdrawn on the strength of that opinion. Twenty years on, no New Zealand court has ever been asked to test it. Australia’s position, by contrast, has now been through a full adversarial hearing, an appeal, and a cross-appeal. On 15 May 2026 the Full Federal Court upheld the finding that Giggle for Girls and its founder had directly discriminated against Roxanne Tickle, affirming the earlier finding that sex under the Sex Discrimination Act is “changeable and not necessarily binary.” That is a reasoned, appealable judgement applying the statute to a real dispute — not an executive opinion nobody has ever had standing to challenge.

The political trajectories are inverted. New Zealand’s Bill passed its first reading 67–55 with a governing-coalition bloc — National, ACT, and NZ First — behind it, and is now before select committee with genuine prospect of progressing. Australia’s three attempts to restore its own removed definitions have gone the other way. Pauline Hanson’s 2024 bill was blocked at first reading — a rare procedural rejection reserved for bills the Senate majority judges too consequential to even formally debate. Alex Antic’s 2025 bill, co-sponsored by the-then Nationals leader, was kept from reaching a vote by Labor and the Greens. Alison Penfold’s bill, tabled on 25 May 2026 in the wake of the Full Court ruling, was introduced by its own sponsor with the acknowledgement that it is “very unlikely to pass” from opposition — her real request was a joint committee to reopen the Act, not passage of her own bill. New Zealand’s correction has institutional momentum Australia’s has never had.

The legislative reach is different in scale. New Zealand’s Bill amends the Legislation Act 2019 — the general interpretive statute that governs how every other NZ law is read. Its effect, if it passes, is not confined to one Act. All three Australian bills amend the Sex Discrimination Act only. A passed Australian bill would still be narrower than what is currently before the New Zealand committee.

What neither fight has said out loud

Put those four differences together and the honest conclusion is not that Australia is somehow further behind than it looks. It is that Australia’s version of this problem is now more entrenched than New Zealand’s, not less — a circular definition that has been judicially applied is harder to dislodge than an executive opinion that has never been tested. That is a genuinely harder fight than New Zealand’s.

But entrenchment in one country’s discrimination law is not the argument that gets a parent, a clinician, or a select committee member to actually stop and think. Sport and single-sex spaces are contested terrain — everyone arrives with a position already formed. Nobody has yet asked either parliament to look at what an untestable term does when it is presented to a family as the settled basis for a child’s medical or social transition. That question sits underneath both countries’ fights and has been raised in neither.

AWW’s submission to the New Zealand select committee makes that argument on the narrowest possible ground: informed consent requires facts that can be checked, and a construct defined only by reference to itself cannot be checked. Whatever the committee decides, the argument is now on the public record in one of the two countries whose clinical practice is built on the same shared guidance. If the Bill progresses, that record becomes something to put in front of officials directly. If it doesn’t, the argument still stands, unanswered, on both sides of the Tasman.

READ: AWW’s Submission to the Social Services and Community Committee, Legislation (Definitions of Woman and Man) Amendment Bill

This piece is a companion to a separate analysis of what the Full Federal Court could and could not test in Giggle v Tickle. The next piece in this series. On the circularity of the Sex Discrimination Act’s “gender identity” definition, and on what happens when that definition is imported into clinical pathways — articles are linked below.

A tester’s approach to the problem of ‘gender identity’ in law - Part 3: When the construct enters commerce

A tester’s approach to the problem of ‘gender identity’ in law - Part 2: When a legal definition becomes a clinical premise

This is a tester’s approach to the problem of ‘gender identity’ in law - Part 1: the circularity problem at the source

AWW is auditing private gender clinics in Australia for compliance with Australian Consumer Law and National Law informed consent standards. See aww.org.au/informed-consent for the full audit corpus.

Catherine Anderson-Karena, Founding Director, AWW Inc. — contact@aww.org.au

What is distinctive about the work I am doing, and why it does work that adjacent approaches do not.

The unique contribution, in one sentence

I have taken a tester’s mindset - the engineering and audit discipline of checking whether something can be operationalised, falsified, bounded, and stopped - and applied it to the legal-clinical construct of “gender identity,” and I have built a structured audit methodology that traces the construct’s definitional defect from statute through clinical operationalisation into consumer-protection exposure, producing regulator-ready outputs across a planned series of clinics.

That synthesis, to the best of my knowledge and AWW’s literature review, this synthesis has not been advanced elsewhere, as far as I can see, it is original. I invite correction.

What the methodology actually does that adjacent work does not

The Cass Review and the York systematic reviews supply the clinical evidence-base critique. They do not make the consumer-law move. They show that the evidence is weak; they do not translate that weakness into a regulator-actionable representational analysis.

Joyce, Stock, Lawford-Smith and others have produced sustained philosophical and policy critique of the construct. They argue what the construct is. They do not, as a rule, trace it through clinical-commerce operationalisation into a consumer-protection framework.

Tickle v Giggle and the Sall Grover line litigate the same SDA s 4 definition I start from. They contest it inside anti-discrimination law. I am working on the same definitional defect through a different door of the building - consumer law rather than discrimination law. That is a different jurisdictional pathway entirely, and it reaches a different remedy.

Bernard Lane at Gender Clinic News and Hannah Barnes’ work on the Tavistock have done investigative journalism. They expose. They do not produce structured compliance audits with templated regulatory outputs.

Genspect, SEGM, Sex Matters and Transgender Trend have done substantial substantive critique and advocacy. The closest international parallel I know is Sex Matters’ UK work - but UK regulatory architecture (CPRs, CMA, ASA, GMC) is different, and that work does not anchor in the consumer-law-applied-to-clinics framework I have built.

What I have not seen anywhere is the combination: definitional defect at the statutory source → operationalisation failure in clinical pathways → consumer-protection exposure under existing law → structured audit methodology → regulator-ready outputs across a planned series → restorationist framing that uses existing frameworks rather than proposing new ones.

That combination is, as far as I can see, original to AWW.

Why this helps the fight — particularly for minors

The consumer-protection frame does not require winning the philosophical or political fight about gender identity. It only requires showing that the representations are capable of misleading a reasonable consumer. That is a lower threshold and a less ideologically loaded one. Regulators can act on a misleading-conduct finding without taking a position on the underlying construct. That matters because regulators are far more comfortable enforcing consumer-protection law than they are adjudicating contested social questions.

For minors specifically, the framework reaches the hinge issue, which is consent. If parents and young people have been led into error about the nature, scientific basis and therapeutic status of the services being offered, then the consent obtained on the basis of those representations is itself compromised. That connects the regulatory analysis to Rogers v Whitaker and the broader common law on material risk disclosure, which is what Part 2 of my series sets up. The consumer-law exposure and the informed-consent failure are the same evidentiary record viewed through two regulatory lenses.

The methodology is forward-portable in several ways. It travels to other jurisdictions with consumer-protection statutes - the UK CPRs and CMA framework, U.S. state attorneys general acting under state UDAP statutes, the EU under UCPD. It travels to other regulatory pathways within Australia - AHPRA s 133, TGA. And it travels to other contested medical fields where the same definitional-operationalisation failure may be present.

The restorationist framing matters strategically. Medical and legal readers are far more receptive to “you are already required to do this under existing standards” than to “we need new law.” The argument deflects the standard ideological response, which is to characterise critics as wanting to impose a new framework. I am not imposing a new framework. I am asking whether existing ones - ACSQHC standards, Rogers v Whitaker, ACL s 18/29, AHPRA s 133 - are being met. That is much harder to dismiss.

And the audit corpus produces evidence that survives political reversal. Whatever the current regulatory appetite, the documentary record exists. If a future regulator, parliamentary inquiry or court wants to act, the materials are there. The work is durable in a way commentary and litigation alone are not.

What I have built is, in plain terms, the regulatory-compliance instrument the field has been missing. Other people have argued that gender medicine is wrong on the science. I have built the instrument that asks whether it is wrong on the law — and the answer, on the evidence I have assembled, is that it is wrong on the law that already exists.

That is a contribution. And it’s one that people are missing.

The latest article is here – King Street Psychological Clinic proves the ‘no stopping rule/no boundary’ flaw ‘gender identity’ construct in healthcare:

A tester’s approach to the problem of ‘gender identity’ in law Part 3: When the construct enters commerce

Catherine Anderson-Karena , www.aww.org.au/informed-consent , contact@aww.org.au

“We offer affirming, scientifically-informed clinical support to individuals who experience feelings related to, or who identify as, otherkin or therians.”

That sentence appears on the Adult Gender & Sexology Clinic page of King Street Psychology Clinic in Sydney. The same clinic represents its Child & Adolescent Gender Service as “the only private clinic in Australia specialising in assessment, diagnosis, family support, and clinical management of gender dysphoria in older children and adolescents.”

That is why this is not a thought experiment.

In Parts 1 and 2, I looked at a threshold problem in Australian law and health care: the legal term “gender identity” is being moved from anti-discrimination law into clinical practice.

Under the Sex Discrimination Act 1984 (Cth), “gender identity” is protected as a legal attribute. The statutory definition refers to a person’s “gender-related identity, appearance or mannerisms or other gender-related characteristics”, with or without regard to the person’s designated sex at birth.

As an anti-discrimination protection, that may be workable. The purpose is to prevent unfair treatment. But it becomes a different problem when the same concept is imported into clinical pathways as though it were an identifiable medical or psychological entity capable of assessment, affirmation, referral, social transition, puberty suppression or cross-sex hormones.

From a testing and compliance perspective, that matters.

A clinical pathway needs something capable of being operationalised. It needs criteria that allow a practitioner, auditor, regulator, patient or parent to distinguish between a valid assessment and an invalid one. It needs some way of identifying what evidence would support the claim, what evidence would call it into question, and what safeguards should apply before intervention occurs.

“Gender identity,” as currently defined and used, does not provide that.

That is where Part 3 begins.

The s 18 question

Under s 18 of the Australian Consumer Law, conduct is misleading or deceptive, or likely to mislead or deceive, if it has a tendency to lead a person into error. The test is objective. It does not require proof that anyone was actually misled. It does not require intention. It is enough that the overall impression is capable of leading the ordinary or reasonable consumer into error.

A private clinic advertising and charging fees for psychological services is supplying services in trade or commerce. The fact that the representation appears on a clinical website rather than a retail shelf does not remove the consumer-law question.

The immediate focus of this article is s 18. Section 29 is also engaged. Section 29(1)(b) prohibits false or misleading representations that services are of a particular standard, quality or value. Section 29(1)(g) prohibits false or misleading representations that services have particular benefits. Both apply where a clinical service is represented as having a particular evidentiary or therapeutic character.

The propositions under test are these:

• That “gender identity” is an identifiable medical or psychological entity.

• That clinical services can validly assess and affirm it.

• That intervention based on affirmation of gender identity is therapeutic and evidence-based.

King Street Psychology Clinic is useful because it crystallises all three propositions in one documented example.

Proposition 1: the represented clinical entity

The first proposition is that “gender identity” is an identifiable medical or psychological entity capable of clinical assessment.

A clinic may try to avoid that problem by saying it does not assess “gender identity” as such. It assesses gender dysphoria, which is a recognised diagnostic category with textual criteria.

That is the obvious legal and clinical pivot. It also exposes the problem.

The materials used by gender clinics do not remain confined to diagnosis and treatment of a dysphoric condition. They repeatedly use the language of gender identity, gender-related milestones, affirmation, gender-diverse identity, gender identity exploration and support for identity-based transition. The pathway is not merely framed as the treatment of distress. It is framed as the assessment and affirmation of an identity.

The slippage is not mine. The slippage is in the materials.

KSPC makes that slippage concrete because its otherkin and therian page cannot retreat into gender dysphoria. There is no DSM-5-TR or ICD-11 diagnosis of otherkin identity. There is no recognised clinical taxonomy for a person who identifies as a wolf, dragon, demon, angel, elf or fox. Yet the clinic represents that it offers “affirming, scientifically-informed clinical support” for people who experience or identify with those categories.

That is the Part 1 “no internal stopping rule” problem made concrete. Once self-attribution becomes the anchor, the construct cannot exclude any case on its own terms. The category changes. The logic travels.

Proposition 2: the represented assessment

The second proposition is that the clinic can validly assess and affirm the identity.

There is nothing wrong with a clinician being kind, non-mocking and careful with a distressed person. People with unusual beliefs or identity claims may be vulnerable. Some may be lonely. Some may be autistic. Some may be traumatised. Some may be immersed in online subcultures. Some may simply be eccentric adults who need ordinary counselling and a safe place to talk.

But you cannot know which until you assess.

That is the problem with a public promise to be affirming and non-pathologising before the person walks through the door. If the conclusion has already been written before differential thinking begins, then the thing being offered may no longer be assessment in the ordinary clinical sense. It may be validation, support, coaching or identity accommodation. Those may be services, but they are not the same as an open-ended clinical assessment.

That distinction matters under consumer law because consumers are not paying merely for warmth or politeness. Parents and patients approach a specialist clinic because it represents clinical authority. They are paying for assessment that is open-ended, differential, and capable of reaching conclusions other than the patient’s self-attribution. They are paying for diagnosis, evidence-based treatment and clinical judgment.

What they are being supplied with, where the pathway has been pre-committed to affirmation before the patient walks through the door, is something with a different character. It may be validation, support, coaching or identity accommodation. Those may be useful services. They are not assessment in the sense the consumer is being asked to pay for. The gap between what is represented and what is supplied is what makes the representation capable of misleading under s 18.

Proposition 3: the represented therapeutic benefit

The third proposition is the strongest s 18 hook: that interventions based on affirmation are therapeutic and evidence-based.

Words such as “evidence-based”, “scientifically-informed”, “clinical management” and “therapeutic” do real work. They invite the consumer to assume that there is a body of science behind the service. They also imply that the service is not merely supportive, ideological, exploratory or preference-based. It is held out as clinically grounded.

This is where the Nurofen Specific Pain case is structurally useful. The misleading representation was not that ibuprofen did nothing. The problem was the representation of clinical specificity: that particular Nurofen products were formulated to specifically treat particular types of pain, when the underlying basis for that specificity was not supported.

The KSPC problem has the same shape. A clinic is not merely saying, “We offer counselling to people who are distressed.” It is representing clinical specificity: assessment, diagnosis, management, affirmation and scientifically-informed support for identity categories. With otherkin and therian identity, the underlying basis for that specificity is absent. With paediatric gender medicine, the evidence base for the headline therapeutic outcomes - puberty suppression and cross-sex hormones in adolescents - has been characterised as low to very low certainty by the University of York systematic reviews underpinning the Cass Review (2024), the U.S. Department of Health and Human Services 2025 evidence review, the New Zealand Ministry of Health briefing, and the Finnish register study by Ruuska et al. (2026). The position is not that nothing works for anyone. The position is that the represented evidentiary base for the clinical specificity does not survive contact with the independent systematic reviews.

That does not require proving that no one ever feels helped. Section 18 does not require that. The question is whether the overall representation has a tendency to lead a reasonable patient or parent into error about the nature, scientific basis, reliability and therapeutic status of what is being offered.

On that question, the phrase “scientifically-informed” is not decorative. It is doing consumer-law work.

Why the gender-dysphoria pivot does not answer the consumer-law problem

The strongest defence is predictable: “The clinic is not treating gender identity. It is assessing gender dysphoria, a recognised diagnosis.”

If a clinic’s materials were confined to careful diagnosis of distress, differential assessment, treatment of co-occurring mental health issues, open-ended exploration and cautious disclosure of uncertainty, the s 18 issue would be narrower.

But that is not how the public-facing ecosystem operates. Websites, intake forms, consent forms and treatment pathways often move between gender dysphoria and gender identity as though they were interchangeable. The diagnostic category supplies clinical respectability. The identity construct supplies the direction of travel. The patient’s self-attribution becomes the operative test.

KSPC’s otherkin and therian page matters because it strips away the rescue category. There is no gender dysphoria diagnosis to shelter behind. There is only the affirmation framework itself, attached to a self-attributed identity category and offered to consumers under the language of scientifically-informed clinical support.

That is why KSPC is not a side issue. It is the cleanest demonstration of the logic.

Materiality: why this matters to patients and parents

For s 18 purposes, the representations matter because they go to the basis of the consumer’s decision.

A parent or patient does not approach a specialist clinic in the same way they approach a lifestyle coach or online identity community. They approach because the clinic represents expertise, clinical authority, evidence-based practice, assessment, diagnosis and therapeutic management.

The foundational status of the construct is therefore not an abstract philosophical fact. It goes directly to whether a reasonable patient or parent would consent to the service, pay for the service, trust the service, or allow a child to be channelled through the pathway.

That is also where this article links back to Part 2. Under Rogers v Whitaker, the question is not whether clinicians are personally convinced of their model. The question is whether a reasonable patient, or this particular patient, would attach significance to the information. The absence of a diagnostic test, biomarker, falsifiable boundary, agreed taxonomy, internal stopping rule or robust evidence for therapeutic benefit is exactly the kind of information a reasonable parent may attach significance to.

What has been put to the ACCC

This is not only an academic argument. On 24 March 2026, an Australian Consumer Law complaint was lodged with the ACCC in relation to King Street Psychology Clinic. That complaint addressed four specific representations: the “scientifically-informed” otherkin and therian service; the WPATH letter-writing service without publicly disclosed assessment criteria; the offer of pre-medical counselling on puberty suppression and cross-sex hormones without publicly accessible risk information; and the representation of evidentiary awareness made alongside the absence of any reference to the Cass Review.

The analysis has developed since then. The s 18 frame set out in this article extends the same approach to the foundational representational issue: the holding-out of “gender identity” as an identifiable clinical entity capable of valid assessment and therapeutic affirmation. That is the next iteration of the work.

The analytical proposition is this:

A clinic, in trade or commerce, represents to patients and parents that it provides assessment and treatment for an identifiable medical or psychological entity described as gender identity. It further represents that its clinical services can validly assess and affirm this entity, and that interventions based upon such affirmation are therapeutic or evidence-based. Where the underlying construct lacks an independent diagnostic test, biomarker, agreed taxonomy, falsifiable boundary or internal stopping rule, and where the evidence base for therapeutic benefit is weak, contested or absent, those representations are capable of misleading patients and parents as to the nature, scientific basis and reliability of the services being offered.

In formal complaint form, the s 18 allegation, applied to a private clinic providing paediatric gender services, would read along these lines:

Misleading or Deceptive Conduct - Section 18 Australian Consumer Law

The clinic, in trade or commerce, makes representations to prospective and current patients and their parents or guardians that:

1. “gender identity” is an identifiable medical or psychological entity capable of clinical assessment;
2. the clinic’s services can validly assess and affirm a person’s gender identity; and
3. interventions based on such affirmation, including social transition, puberty suppression and cross-sex hormones, are therapeutic or evidence-based.

These representations are made through website statements, promotional materials, intake and assessment forms, consent materials, clinical correspondence and consultations.

The representations are capable of being misleading or deceptive, or likely to mislead or deceive, within the meaning of s 18 of the Australian Consumer Law. They may also engage s 29(1)(b) and s 29(1)(g), insofar as the services are represented as being of a particular standard, quality or value, or as having particular benefits.

The statutory definition of “gender identity” in s 4 of the Sex Discrimination Act 1984 (Cth) is circular and self-referential. It provides no independent biomarker, diagnostic test, agreed taxonomy, falsifiable boundary or internal stopping rule. In the absence of any objective means of identifying or verifying the claimed entity, representations that it constitutes an identifiable clinical condition capable of valid clinical assessment and therapeutic intervention have a tendency to lead patients and parents into error as to the nature, scientific basis and reliability of the services being offered.

The clinic operates as a commercial provider of health services for which fees are charged. By making the above representations without clearly disclosing the lack of empirical foundation for the underlying construct, the absence of objective diagnostic verification, and the contested or low-certainty status of claims regarding therapeutic benefit, the clinic’s conduct is misleading or deceptive, or likely to mislead or deceive.

The same construct, a different legal pathway

The SDA s 4 definition is also being tested in anti-discrimination litigation, including the Tickle v Giggle line of cases. That is one jurisdictional pathway. It asks how the construct operates inside discrimination law.

Part 3 asks a different question. What happens when the same construct travels downstream into clinical commerce? What happens when a legal definition created to prevent discrimination is imported into clinical services, held out as assessable, affirmable, scientifically-informed and therapeutic, and sold to consumers as a specialised health service?

That is the consumer-law exposure.

KSPC is not the strongest example because it is the most colourful. It is the strongest example because it shows what the construct does when no other diagnostic category is available to dress it in. The same analysis operates wherever the affirmation framework operates, regardless of which identity category is being affirmed.

The category changes. The representational problem remains.

The audit corpus underpinning this analysis - private gender clinics audited against Australian Consumer Law, the National Law, and the ACSQHC informed consent standards - is available at aww.org.au/informed-consent.

Source links / publication notes

1. King Street Psychology Clinic, Adult Gender & Sexology Clinic, Otherkin and Therian Experiences

2. King Street Psychology Clinic, Child & Adolescent Gender Services

3. Sex Discrimination Act 1984 (Cth), Federal Register of Legislation

4. Competition and Consumer Act 2010 (Cth), Schedule 2 Australian Consumer Law

5. ACCC media release, Full Federal Court orders $6 million penalty for Nurofen Specific Pain products

6. Cass Review Final Report

7. Taylor et al. 2024, Interventions to suppress puberty in adolescents experiencing gender dysphoria/incongruence: a systematic review

8. Taylor et al. 2024, Masculinising and feminising hormone interventions for adolescents experiencing gender dysphoria or incongruence: a systematic review

9. Ruuska et al. 2026, Psychiatric Morbidity Among Adolescents and Young Adults Who Contacted Specialised Gender Identity Services in Finland in 1996-2019

10. New Zealand Ministry of Health briefing, Puberty blockers for young people with gender incongruence and dysphoria: policy options

11. U.S. HHS, Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices

12. Rogers v Whitaker (1992) 175 CLR 479

13. Analogy: The Missing Load-Bearing Wall When affirmation replaces diagnosis, the structure of ethical medicine begins to fail.

14. Full Federal Court orders $6 million penalty for Nurofen Specific Pain products

A legal definition created to prevent discrimination (’gender identity’) is being imported into clinical pathways as though it were an empirically settled medical premise.

Rogers v Whitaker forces a question Australian gender clinics have not been asked to answer: is the diagnostic premise itself a material fact?

One of the problems with the s 4 Sex Discrimination Act 2013 definition of “gender identity” from a regulatory perspective is that it is impossible to test — the definition is circular, as set out in Part 1 of this series

.The issue is not simply that the Sex Discrimination Act protects “gender identity” as a legal attribute. Parliament may create broad protective categories for anti-discrimination purposes. The problem arises when that legal category is imported into clinical pathways and treated as if it were an empirically settled medical premise.

If a clinic recommends social transition, puberty blockers, cross-sex hormones, or referral pathways on the basis that a child or adolescent has a “gender identity” requiring affirmation, then the status of that premise matters. Parents and patients are entitled to know whether the premise being relied on is objectively testable, diagnostically defined, and clinically distinguishable from other explanations for distress.

On that basis, the absence of a biomarker, diagnostic test, agreed definition, or falsifiable boundary is not a side issue. It is potentially material information. It goes to the foundation of the proposed pathway, not merely to the physical side effects of treatment.

That is the question this piece works through: how to frame the circularity and workability problem as a testable compliance gap in the private gender clinic and guideline audits AWW is producing.

What follows is a tester’s perspective, not a lawyer’s. Compliance work has to deal with the law as it stands. Corrections welcome.

That brings the issue squarely into informed consent. Australian gender clinics are not merely using “gender identity” as a social descriptor. They are using it as a clinical decision-point: something that can justify affirmation, social transition, referral pathways, puberty suppression, cross-sex hormones, or other medical interventions.

If that is so, the audit question becomes practical: where a clinic’s pathway depends on accepting “gender identity” as a clinically meaningful premise, does the consent process disclose the limits of that premise? If it does not, the problem is not merely poor wording or a philosophical disagreement. It is a potential informed-consent gap at the foundation of the pathway itself.

The Rogers framework

In our existing audit framework, Rogers v Whitaker (1992) 175 CLR 479 requires disclosure of material risks, where materiality is judged by what a reasonable patient (or a particular patient) would attach significance to. The doctrine explicitly rejects the Bolam test of ‘professional consensus as sufficient’.

In Rogers, the High Court rejected the Bolam test for the duty to disclose information.

• Bolam (the “reasonable body of medical opinion” test) applies to the standard of care in performing treatment.

• It does not apply to the duty to warn or disclose.

• The Court held that the test for disclosure is patient-centred: a doctor must disclose a risk (or other material information) if:

• a reasonable person in the patient’s position would be likely to attach significance to it, or

• the doctor knows or ought reasonably to know that the particular patient would attach significance to it.

This is a deliberate shift away from professional consensus as the controlling standard for what must be disclosed.

This Bolam-for-disclosure rejection matters in this context, because the standard defence - “this is the prevailing clinical consensus” - does not help on the disclosure question. Consensus answers the Bolam standard-of-care question; it does not answer the Rogers materiality question.

The question

Framed this way, the question is not whether “gender identity” should be protected from discrimination. The question is whether a clinic may rely on “gender identity” as a clinically meaningful premise without disclosing that the construct has no objective diagnostic test, no biomarker, no agreed scientific definition, and no falsifiable boundary.

The diagnostic encounter may present the construct as settled clinical fact. Disclosing only the physical risks of treatment, while presenting the clinical premise as established, may leave out information that a reasonable patient or parent would attach significance to.

So the question for audit purposes becomes this: how is the contested status of the underlying clinical premise not potentially material under Rogers? This is distinct from, and additional to, the well-established disclosure failures around puberty blocker reversibility, fertility, sexual function, bone density, neurocognitive uncertainty, and the rest.

Applying it to the contested status of “gender identity”

Draft argument:

Because a gender-affirming pathway uses “gender identity” as a clinical decision-point, the evidential status of that premise is potentially material information. A reasonable patient, or the parent of a minor patient, may attach significance to knowing that the concept being relied on is self-reported, has no objective diagnostic test, has no biomarker, has no agreed scientific boundary, and is clinically contested. Failure to disclose this raises a Rogers materiality issue, independent of the physical risks of the interventions themselves.

Strengths of the argument

• Rogers is deliberately broad. It is not limited to “physical risks of the procedure.” The High Court spoke in terms of information that enables the patient to make an informed choice about whether to undergo the proposed treatment at all. The underlying premise of the treatment can plausibly fall within that.

• Patient autonomy focus. The case rejected paternalism. If the entire treatment pathway rests on accepting a contested construct as clinical fact, a reasonable parent could attach real significance to knowing:

• there is no objective test for the condition being treated;

• the construct has no agreed scientific definition or boundary;

• the model has been heavily criticised in recent systematic reviews (Cass, NICE, SBU, COHERE, US HHS); and

• high rates of comorbidities exist that may explain the distress.

• Rejection of Bolam helps. The fact that “most gender clinicians don’t disclose this” is not a defence under Rogers. Professional consensus does not set the disclosure standard.

• Particularly strong for minors. Parents making decisions for children have a heightened interest in knowing foundational uncertainties. Courts have shown some willingness to scrutinise information given to parents in high-stakes paediatric cases.

Weaknesses and practical difficulties

• Novel extension. Australian courts applying Rogers have mostly dealt with risks of physical or psychological harm from the treatment itself, not with disclosure that the diagnostic construct or model of care is scientifically contested. Extending it to the “ontological status of the concept” is a significant step. As far as I have checked, it has not been tested in this context.

• “Materiality” is fact-specific. One would ultimately need to persuade a court (or regulator) that a reasonable patient or parent would attach significance to this information. That is arguable, but not automatic. Opposing evidence could include:

- many patients / parents say they already knew it was based on self-report and still wanted to proceed;

- prevailing guidelines (AusPATH and others) present gender identity as a valid clinical entity.

- clinicians argue that the relevant clinical presentation is distress, impairment, or persistence, not “gender identity” in isolation.

• Legal category vs clinical premise. The argument needs to keep the distinction clear. The Sex Discrimination Act may protect “gender identity” as a legal attribute. That does not make it a diagnostic construct. The compliance problem arises when the legal category is treated as a clinical premise without disclosure of its evidential limits.

• Causation and loss. Even if non-disclosure is a breach, the patient or parent would still need to show they would have made a different decision if properly informed. From what I have studied this is often the hardest part of Rogers cases.

• Regulatory vs court context. This argument is stronger as a compliance / regulatory pressure point (AHPRA notifications, health complaints commissions, ACCC misleading conduct, supporting complaints under conversion practices laws) than as a guaranteed winning court case. Regulators can act on patterns of inadequate disclosure without needing to prove individual causation and loss.

Audit questions

The practical audit questions are:

• Does the consent record show that the patient or parent was told there is no objective diagnostic test for “gender identity”?

• Does the clinic distinguish between legal protection of “gender identity” and clinical validation of “gender identity” as a treatment premise?

• Does the clinic disclose that the construct is self-reported and lacks a falsifiable boundary?

• Does the clinic document assessment of alternative explanations for distress, including mental health, trauma, autism, sexuality, family dynamics, social contagion, or other comorbidities?

• Does the clinic’s website or advertising create the impression that “gender identity” is a verifiable clinical attribute?

• Does the guideline explain how clinicians, auditors, or regulators can distinguish compliant from non-compliant use of the criterion in practice?

Overall assessment

I think the argument is coherent and worth pursuing, especially when framed carefully. It is not obviously wrong, and the post-Cass / HHS / Vine shift in the evidence base makes it more credible than it would have been in 2018–2022.

The cleanest and strongest version is probably this:

The duty under Rogers v Whitaker requires disclosure of information that a reasonable patient (or parent) would attach significance to in deciding whether to undergo the proposed pathway. Where the entire pathway is predicated on the existence and clinical validity of “gender identity” as a discrete phenomenon, the absence of any objective test, agreed definition, or robust empirical foundation for that construct is itself material information. This is distinct from - and additional to - disclosure of the physical risks of the interventions.

This argument ties to concrete, documented failures in the AWW audits:

• consent forms that only list physical side effects;

• no discussion in clinical notes of the lack of diagnostic testing;

• no distinction between legal protection and clinical validation;

• no mention of comorbidity rates or the contested evidence base.

• website or patient information claims that present “gender identity” as though it were an established clinical fact.

1. Version tailored for AHPRA notification (practitioner obligations)

In Rogers v Whitaker (1992) 175 CLR 479 the High Court held that the duty to disclose material information is determined by what a reasonable patient (or parent) would regard as significant, and expressly rejected the Bolam test of professional consensus. The clinic’s failure to disclose that “gender identity” has no objective diagnostic test, rests on a circular statutory definition, and remains scientifically contested means that parents and patients were not provided with material information required to make an informed decision about commencing social or medical transition. This constitutes inadequate disclosure contrary to the practitioner’s obligations under the Health Practitioner Regulation National Law and the Medical Board of Australia, Good Medical Practice: A Code of Conduct for Doctors in Australia - particularly s 4.5 (Informed Consent) and s 4.6 (Children and Young People) - to practise in an evidence-based manner and to obtain valid informed consent.

2. Version tailored for ACCC complaint (misleading conduct)

The clinic represents that it provides evidence-based gender-affirming care, but the service appears to rest on the premise that “gender identity” is a clinically meaningful and verifiable attribute. Under Rogers v Whitaker (1992) 175 CLR 479, the contested status of that premise, including the absence of any biomarker, diagnostic test, agreed scientific definition, or falsifiable boundary, is information that a reasonable patient or parent may attach significance to. By failing to disclose this, while presenting the pathway as evidence-based and clinically settled, the clinic’s overall conduct in trade or commerce is capable of being misleading or deceptive in breach of s 18 of the Australian Consumer Law. It may also constitute false or misleading representations about the characteristics, benefits, and therapeutic suitability of its services for the purposes of s 29 of the Australian Consumer Law.

Sources and further reading

Part 1 of this series: “A tester’s approach to the problem of ‘gender identity’ in law - Part 1: the circularity problem at the source.”

Earlier discussion of the circularity issue:

x.com/KatKarena/status/2067953114377048384

UNSW Law Journal, Vol 33(2):

unsw.edu.au/content/dam/pdfs/law/unsw-law-journal/2010-2019/Vol-No-33-2-10.pdf

Two Pathways. One Phrase:

and

The Two Systems of Health Care:

and

When a Children’s Medical Guideline Fails the Safeguard Test:

Catherine Anderson-Karena @contact@aww.org.au | www.aww.org.au/informed-consent/

Part 1: the circularity problem at the source

This is a regulatory design tension created in 2013.

Core framing for our audit reports on the circularity problem of the gender identity definition in law:

“The Sex Discrimination Act’s s 4 definition of ‘gender identity’ is circular and lacks any independent, observable, or testable referent. In the absence of any statutory taxonomy, diagnostic test, or internal limit, a clinic cannot demonstrate consistent, evidence-based operationalisation of the protected attribute when providing clinical services. This creates a compliance gap against the AHPRA Shared Code of Conduct, the ACSQHC National Safety and Quality Health Service Standards (Clinical Governance and Partnering with Consumers), and the evidence-based practice expectations under the National Law.”

From a strict compliance and testing perspective, the definition of ‘gender identity’ as per the SDA and conversion therapy laws in Australia creates genuine workability problems - especially once it moves from pure anti-discrimination law into medical practice, clinical decision-making, and regulatory oversight.

Here is the direct analysis.

1. The definition is structurally circular and unanchored

The SDA s 4 definition defines “gender identity” by reference to “gender-related identity… or other gender-related characteristics.” There is no external referent, no diagnostic criterion, no measurable property, and no statutory taxonomy or limit. The definition creates interpretive ambiguity that cannot be resolved internally -- what counts as “gender-related appearance” or “mannerisms” when those can be culturally variable or unrelated to any underlying trait?

The 2013 amendment was framed as giving “maximum protection” by treating gender identity as a purely subjective, self-defined attribute, decoupled from sex.

The downstream consequence is that the construct has no principled stopping rule. The

AWW King Street Psychological Clinic observation

-- affirmation extending to non-human identities -- illustrates the absence of an internal limit. The point is not that non-human identities are the typical case. The point is that once the only anchor is self-attribution, the case cannot be excluded on the construct’s own terms.

2. In pure anti-discrimination law, this is workable (barely)

Anti-discrimination statutes often protect subjective or internal attributes (religious belief, political opinion, etc.). You do not need an objective test to prohibit someone from being fired or refused service because of their stated gender identity. Courts can still ask the factual question: was the adverse treatment motivated by the person’s claimed identity?

Recent cases (Tickle v Giggle [2024] FCA 960) show courts applying the provision without collapsing into incoherence. The Federal Court’s reasoning in that case actively embraced the subjective interpretation, which confirms two things at once: the definition is administrable in pure anti-discrimination contexts (the point of this section), but the legal system has now operationalised the maximally subjective reading, which sharpens the downstream problem identified in Section 3.

So in the narrow SDA discrimination context, the definition functions as a broad protective umbrella. It is vague and expansive, but not legally impossible to administer.

3. But in medical, clinical and regulatory contexts, it creates compliance impossibility

This is where the tester’s lens shows where the real problem lies. The same analysis a senior tester applies to any requirements specification - the context-driven testing logic Bach and Bolton developed for software - is what I am applying to a regulatory artefact here.

• No observable referent or test means a practitioner cannot independently verify what they are being asked to affirm, diagnose, or treat. The entire clinical pathway rests on self-report.

• No agreed taxonomy or limit means the protected attribute can (and in practice does) expand without boundary. The non-human identities case earlier is the reductio: there is no principled ceiling within the construct.

• Evidence-based practice obligation under the Health Practitioner Regulation National Law (and AHPRA’s code) requires practitioners to have a reasonable clinical basis for their actions, grounded in available evidence, and to practise within the limits of their competence and the evidence.

When the foundational construct (“gender identity”) has no independent empirical anchor, and the dominant model treats affirmation of whatever is self-reported as the default therapeutic response, this clashes with evidence-based requirements. The international shift - Cass Review systematic reviews showing weak evidence for routine medical affirmation in minors, plus restrictions in Sweden, Finland, England, the Netherlands — makes continued reliance on the pre-2024 affirmation model increasingly difficult to defend as “evidence-based.”

4. The conversion practices carve-outs expose the same flaw

State laws (Victoria’s Change or Suppression (Conversion) Practices Prohibition Act 2021, and equivalents in the ACT and Queensland) contain health practitioner carve-outs phrased around “reasonable professional judgement.” Those carve-outs are only as robust as the underlying clinical model. If the model itself rests on an untestable, circular, and increasingly contested construct, then the “reasonableness” of affirming whatever the patient declares their gender identity to be becomes contestable — especially when high rates of comorbidities, desistance data, and weak evidence for medical interventions are taken into account.

The carve-out was written assuming the affirmation model was settled clinical practice. That assumption is increasingly contested and is not universally accepted.

Bottom line, from a compliance standpoint

The definition does not make the discrimination prohibition unworkable. It does make consistent, evidence-based, testable compliance extremely difficult once the attribute is used to justify medical interventions, school policies, or regulatory carve-outs for “affirming” care.

In software or regulatory compliance testing, if a requirement has no verifiable input, no defined output boundaries, and no way to determine pass/fail independently of the subject’s assertion, you flag it as untestable. The same logic applies here. The definition is not legally void, but it is regulatorily fragile - particularly as the evidence base for the clinical model built on top of it has shifted. That fragility is exactly what creates ongoing compliance risk for practitioners and regulators who must operationalise it.

Catherine Anderson-Karena,
https://www.aww.org.au/informed-consent

This article argues that AusPATH’s Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy (Version 2, 2025) invokes the ordinary legal and regulatory meaning of informed consent, then uses the same phrase to describe a different clinical pathway. Audits of the document and of private gender clinics applying its model demonstrate that this pathway lowers or removes the diagnostic, assessment, and alternative-treatment safeguards that informed consent is ordinarily understood to require.

The Linguistic Problem

In Australian health care, “informed consent” has a specific operational meaning. It is set out by the Australian Commission on Safety and Quality in Health Care (ACSQHC) and underwritten by the legal duty to warn articulated in Rogers v Whitaker (1992). That duty is measured by what a reasonable person in the patient’s position would likely attach significance to -- not by what the clinician considers relevant. Failure to warn of a material risk under this test is a breach of the healthcare provider’s duty of care.

Informed consent is not merely agreement to treatment. It is a process by which a person is given the information necessary to make a voluntary decision about a specific health intervention.

The ACSQHC defines informed consent as:

“A person’s decision, given voluntarily, to agree to a health care treatment, procedure or other intervention that is made following the provision of accurate and relevant information about the healthcare intervention and alternative options available; and with adequate knowledge and understanding of the benefits and material risks of the proposed intervention relevant to the person who would be having the treatment, procedure or other intervention.” (quoted in AusPATH SOC 2025, p.12)

The definition contains four required elements. The decision must be voluntary. The person must be given accurate and relevant information about the alternative options available. They must be informed of the benefits and material risks of the proposed intervention. And they must have adequate knowledge and understanding before agreeing.

In other words, consent is not informed simply because a person says yes. It is informed only if the person has been given enough information to understand the intervention, the likely benefits, the known and uncertain risks, and the reasonable alternatives, including the option of refusing or delaying treatment.

The ACSQHC capacity framework further requires a person to be able to weigh the consequences of treatment choices, including the choice to refuse treatment. A person cannot meaningfully weigh that choice if no real alternative to the proposed intervention has been presented.

What this framework requires is not unusual or onerous. It is the same process that governs informed consent across Australian medicine - for oncology, surgery, paediatrics, and complex psychiatric presentations including eating disorders and identity disturbance in adolescents. The standard is not insufficient for gender-distressed patients. It is the standard medicine ordinarily applies to distress.

NB: The Medical Board’s Good Medical Practice Code aligns with the principles of the standard medical model, requiring doctors to provide balanced, evidence-based information so patients (and guardians of minors) can make voluntary decisions with adequate understanding of benefits, risks, and uncertainties. Table 1 from Regulatory Concerns AHPRA-ACON found on

https://www.aww.org.au/health-professionals

What AusPATH Calls the “Informed Consent Model”

AusPATH’s 2025 Standards of Care adopts the same phrase to describe a different process. On page 12 of the document:

“Under this model, the threshold for initiation of GAHT is simply informed consent. … As GPs, our role is to facilitate and respect these choices.”

And:

“It rejects the idea that a medical professional must validate an individual’s gender experience.”

And, on page 13:

“AusPATH SOC 2025 recommends primary care practitioners adopt a supportive, informed approach, offering hormone therapy, counselling, or other interventions based on the individual’s self-identified needs rather than rigid diagnostic criteria.”

This is the same two-word phrase the ACSQHC uses, but it describes a different process. The clinician’s role is reframed as facilitative rather than evaluative. The threshold for initiation of treatment is the consent itself - not consent following the disclosures, capacity assessments, and consideration of alternatives the ACSQHC requires.

Where the Two Pathways Diverge

The audit of AusPATH SOC 2025 reveals three structural findings that show its operational model does not align with the ACSQHC definition it cites. Each is documentary, verifiable on inspection, and independently sufficient.

Finding 1 - Internal inconsistency on a single page

AusPATH quotes the ACSQHC definition (which contains the four required elements: voluntary decision, alternatives, material risks, and adequate understanding) and then, four paragraphs later on the same page, describes a model that omits two of those elements.

No alternative to gender-affirming hormone therapy (GAHT) appears anywhere in the document’s 76 pages. The terms “exploratory psychotherapy,” “watchful waiting,” and “no treatment” do not appear at all. Mental health support is positioned as an adjunct to GAHT, not as an alternative pathway. Mental health conditions are explicitly excluded as contraindications:

“Mental health conditions, including eating disorders and neurodiversity, are not contraindications for initiating GAHT under the informed consent model.” (p.20)

The document specifies no process by which the clinician verifies that the patient has “adequate knowledge and understanding of the benefits and material risks” beyond tick-box acknowledgements in the Appendix B consent forms.[1]

Because AusPATH cites the ACSQHC definition and then describes a model that omits two of its four required elements, clinics following the AusPATH model cannot satisfy ACSQHC informed consent requirements as a matter of structure, regardless of individual clinician practice.

Finding 2 - Structural impossibility of satisfying the ACSQHC capacity test

Even on its own terms, the AusPATH model cannot satisfy the legal capacity test for valid consent. The ACSQHC capacity framework contains six elements that a person must satisfy for consent to be valid. The fifth requires the patient to weigh up the consequences of treatment choices, including the choice to refuse treatment.

As established under Finding 1, AusPATH SOC 2025 presents no alternative to GAHT. If no alternative has been offered, there is nothing to weigh. A clinician cannot verify that a patient has weighed alternatives when none have been presented. The protocol therefore structurally cannot deliver what the law requires.

This is not an argument about whether individual clinicians do or do not properly assess capacity in practice. It is an argument that the protocol they are instructed to follow does not contain the inputs the assessment requires. The exposure exists independent of the clinician’s intention or care.

Finding 3 - Failure to disclose material risks under the Rogers v Whitaker test

The Rogers v Whitakertest, set out earlier, measures material risk by what a reasonable person in the patient’s position would attach significance to.[2]The two consent forms in Appendix B of AusPATH SOC 2025 make no reference to the following matters that a reasonable person considering gender-affirming hormone therapy would likely attach significance to:

• The findings of the Cass Review (final report, April 2024), which characterised the evidence for gender-affirming hormone therapy in adolescents and young adults as of low quality;

• The University of York systematic reviews (2024), which graded the certainty of evidence for outcomes of cross-sex hormones as low or very low for the majority of outcomes assessed;

• The United States Department of Health and Human Services Review (May 2025), which characterised the evidence base as poor;

• GRADE certainty-of-evidence ratings from the systematic reviews;

• Detransition rates as reported in contemporary literature;

• Persistence of mental health comorbidities post-treatment;

• Lifelong medical dependency (ongoing hormone therapy, monitoring, and management of complications across the lifespan).

These omissions are verifiable on inspection of Appendix B. The consent forms acknowledge some irreversible changes (e.g., deepened voice, increased facial and body hair under testosterone) and contain the general statement that research is ongoing to fully understand the extent and likelihood of these risks, but omit the existence of major independent systematic reviews that characterise the supporting evidence as low or very low certainty. AusPATH SOC 2025 was published in 2025 - more than twelve months after the Cass Review and the York reviews became available. The document’s 143-item reference list cites none of them.

Why This Matters Beyond the Technical Findings

The phrase “informed consent” carries the entire moral and legal authority of medical ethics - Rogers v Whitaker, the Charter of Healthcare Rights, the National Safety and Quality Health Service Standards. When a clinic asserts that “informed consent has been obtained,” every regulator, court, parliament, journalist, and parent reads that assertion against the ACSQHC specification. They have no reason to imagine a second, narrower specification exists.

The two-word phrase therefore does the work of legitimising a process that has been quietly hollowed out of its load-bearing elements. Once “informed consent” can mean two different things while sounding like one, the safeguards that depend on it stop functioning as safeguards. They become labels on doors that no longer open onto the rooms they describe.

Restoration, Not Reinvention

Nothing new needs to be invented to address this. The diagnostic process, the consideration of alternatives, the verification of understanding, and the disclosure of evidence quality are already in the standard medical model. The Cass Review did not propose a new framework for gender medicine; it proposed returning to the existing one. The restoration of ordinary medical practice - applied to this patient population as it is applied to every other - would address the structural problems identified above.

This is a restorationist argument, not a radical one. It does not ask clinicians to learn anything new. It asks that the standards that already govern Australian medicine continue to govern it here.

How this divergence came about - through which documents, which references, which decisions, over what timeline - is a separate question, for another article. This piece is concerned with what the words now do.

One doorway leads to ordinary high-quality medical care. The other leads to a predetermined pathway of gender-affirming care that bypasses safeguards and minimises material risks - all under the same reassuring label.

Highly recommend “WellBN clinic: a model of gender affirming care” from Transgender Trend - WellBN is a documented case in point - understand the same scenario is in play in Australia, as Transgender Trend has said:

“WellBN clinic did not practise healthcare, they practised gender affirming care. The reckless disregard for children's health and safety is a feature, not a bug, of the gender affirming care model.”

Notes

[1] An informal legal review by one Australian lawyer concluded that the Appendix B consent forms function primarily as legal waivers rather than as instruments of informed consent. A broader legal analysis of the forms would strengthen this characterisation.

[2] Rogers v Whitaker(1992) 175 CLR 479 - material risk disclosure standard.

An audit of Australia’s paediatric gender guideline raises serious questions about evidence, informed consent and diagnostic safeguards.

When we treat children in medicine, we apply more care, not less. The younger and more vulnerable the patient, the higher the duty to get the basics right: current evidence, full disclosure of risks, and clear processes for who decides what. This is not contentious. It is how Australian medicine is meant to work, and it is what parents, regulators and the courts assume when they trust a paediatric clinical standard.

So when a guideline governing irreversible medical interventions in children appears to fail ordinary safeguard tests, that is a matter the public is entitled to know about.

Active Watchful Waiting Inc. has audited the

Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents, Version 1.4

— published in November 2023 by the Royal Children’s Hospital Melbourne and endorsed by the Australian Professional Association for Trans Health (AusPATH). The audit applies ordinary Australian regulatory frameworks: the National Health and Medical Research Council’s standards for clinical guidelines, the Commission on Safety and Quality in Health Care’s informed consent framework, the AHPRA Code of Conduct, and the High Court’s settled standard for material-risk disclosure in Rogers v Whitaker (1992). Three findings emerged. Each one stands on its own. Each can be verified in minutes by reading the document itself.

A reference list that stops in 2017

The first finding is the simplest. The guideline has seventy references. Every one of them is dated 2017 or earlier. There are no references from 2018, 2019, 2020, 2021, 2022 or 2023 — not in the original document, and not added in the Version 1.4 update. Anyone can check this: pages 31 and 32 list every reference.

What happened in the missing six years was not minor. The Cass Review interim report appeared in 2022. The UK’s NICE issued evidence reviews on puberty blockers and gender-affirming hormones in 2021. Sweden’s Karolinska Institute and Finland’s COHERE national authority both revised their guidance. The Tavistock children’s gender service in London was reviewed and announced for closure. None of this is footnoted, cited or addressed in the Australian standard for paediatric care. The 2023 update added a substantial new section on GP-led prescribing — but added not a single 2018–2023 reference. The omission is documentary. Whether oversight or selection, it is a problem against the NHMRC’s Standard 6 (evidence base) and Standard 8 (currency and updating) for clinical practice guidelines.

“Informed consent has been obtained”

The second finding concerns informed consent. The guideline’s only consent requirement is that “informed consent has been obtained” (pages 23 and 24). There is no consent form template. There is no minimum list of disclosures that must be made before consent can be considered valid. There is no process for verifying that the young person and their family actually understand what they are consenting to.

The document acknowledges, in its own body text, that the long-term impact of puberty suppression on bone mineralisation is “unknown” (p. 15), that the effect of testosterone on reproductive potential when taken in adolescence is “unknown” (p. 13), and that there is “no empirical evidence” for the appropriate age to introduce hormones (p. 16). None of these acknowledgments is converted into a required disclosure in the consent process. They appear in the document, but the document does not require they appear in the conversation.

What Rogers v Whitaker actually decided

To see why this matters, the relevant case is Rogers v Whitaker — a 1992 High Court decision that still defines what informed consent means in Australian law.

In the late 1980s, a woman named Marlene Whitaker had eye surgery to improve vision in her right eye. Her surgeon, Dr Rogers, did not warn her of a rare complication: that operating on one eye could trigger a condition called sympathetic ophthalmia, causing blindness in both eyes — including the healthy left eye that was not being operated on. The risk was approximately one in fourteen thousand. It happened. She lost almost all her sight.

The High Court ruled the surgeon negligent — and in doing so, set the modern Australian standard for informed consent. The court rejected the older idea that doctors only had to tell patients what other doctors would normally tell them. Instead, it established a patient-centred test: a risk is “material,” and must be disclosed, if a reasonable person in the patient’s position would be likely to attach significance to it, or if the doctor knows this particular patient would.

It is not about how rare the risk is. It is about whether a person making the decision would want to know.

That is the standard a parent considering puberty blockers or cross-sex hormones for their child is owed — and the standard a young person is owed where they are competent to consent. The guideline acknowledges, in its own pages, that bone effects are unknown, that fertility effects are unknown, that the right age to begin hormones is unknown. A reasonable parent in those circumstances would attach significance to that. The guideline does not require the clinician to say it.

Mandatory or discretionary?

The third finding is an internal inconsistency. The guideline specifies, as a mandatory criterion for both puberty suppression and gender-affirming hormones, a diagnosis of Gender Dysphoria in Adolescence made by a mental health clinician with expertise in child and adolescent development and psychopathology (pages 23 and 24, criterion 1).

The Version 1.4 update — the new GP section — describes a primary-care-led prescribing pathway in which mental health referral is treated as discretionary. GPs “should discuss this with patients and offer referrals to psychologists, psychiatrists, or other mental health professionals if and as required” (page 21). The document does not state which passage governs. A GP relying on the new section may believe themselves to be in compliance with the guideline while not satisfying the guideline’s own mandatory criterion.

Australia’s legal framework for paediatric gender medicine — set out in Re Kelvin (2017) and Re Imogen (2020) — assumes that the clinical assessment underpinning treatment has been conducted to a specified standard. The Family Court in Re Kelvin declined to require court authorisation for stage 2 hormone treatment in undisputed cases on the basis that the prevailing Australian clinical guidelines provided adequate safeguards. Where the guideline itself is internally inconsistent about whether mental health diagnosis is mandatory or discretionary, that presumption is exposed. Assessment is a safeguard. It is not an obstacle to care; it is the process that makes care safe.

The test is not ideology

None of this requires anyone to hold a position on the contested clinical questions around gender-affirming care for minors. It does not require trust in one camp or another. The audit asks a narrower and more answerable question: does the document meet ordinary Australian standards for clinical guidelines? Does it engage with current evidence? Does it specify a consent process? Is it internally consistent?

The more vulnerable the child, the stronger the safeguards should be. Yet Australia’s paediatric gender guideline appears weakest precisely where safeguards matter most — current evidence, informed consent and clear diagnostic assessment. That is not an ideological objection. It is a regulatory one. And it is verifiable in minutes by anyone willing to read the document.

• Link to audit here: Royal Children’s Guidelines for Transgender Minors
  

• Oracle testing of the Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents, Version 1.4 against regulatory frameworks.
  

• Small postscript on one of the frameworks, while ASTGTG v1.4 is not formally NHMRC-approved, peak-body-endorsed standards are expected to align with these national quality expectations. It does not.
  
  

by Catherine Anderson-Karena
Active Watchful Waiting Inc.
contact@aww.org.au

I ran the first Tiny House building course in Australia - so I see a few good analogies for gender medicine. Stop. Hear me out. I picked up a few things about structures, codes and what happens when people misclassify serious work as minor work.

Most building codes let you do “cosmetic” or “like-for-like” repairs without a permit - repaint, replace a window, patch plaster. No inspection, no approval, because by definition you’re not changing anything structural. The rule exists so trivial work isn’t drowned in red tape. Now imagine someone uses that exemption to quietly remove a load-bearing wall. The paperwork still says “minor repairs.” The house looks the same from the street. Nobody inspects it, because the category tells them there’s nothing to inspect. The building stands - until it doesn’t.

That is the category error at the heart of gender medicine.

In all other fields of medicine the load-bearing wall is the standard medical model - it’s a process of diagnosis: listening, assessing, investigating, researching current evidence, considering all that, and then making a diagnosis or treatment recommendation. This process is the structure that holds ethical medicine up. It’s encoded in the Medical Board’s Good Medical Practice Code, which requires doctors to provide balanced, evidence-based information so patients, parents, guardians and minors can make voluntary decisions with adequate understanding of benefits, risks, and uncertainties.

But in gender medicine, the architects of “gender-affirming care” removed that load-bearing wall and replaced it with something that looks similar from the outside: affirmation. A partition wall, painted to match. It holds nothing up.

It may use medical language.

It may sit inside clinics.

It may appear in referral pathways.

It may be described as compassionate care.

But if the diagnostic process has been replaced by affirmation, then the structure has changed. And that matters.

We are now seeing the floor begin to collapse under the weight of irreversible harms, poor-quality evidence, worsening distress in some studies, permanent bodily consequences, broken families, and young people who were never properly assessed before being placed on life-altering pathways.

Attention goes to the visible cracks - court cases, regret, medical injury, family breakdown, suicide claims, political fights. That’s what makes the news. That’s the drama. But the cracks aren’t the problem. The wall that’s missing is.

A small category error can cause a huge structural shift. Regulators need to inspect the structure before more young people are harmed.

The question regulators should be asking is not merely: “Was this called gender-affirming care?”

The question should be: “Did this clinic actually follow the ordinary standards of medical assessment, informed consent, risk disclosure, diagnosis, evidence review, and professional care?”

A label is not a load-bearing wall.

Calling a treatment pathway “gender-affirming care” does not exempt it from ordinary medical, legal, consumer, and professional standards.

That is why regulators must inspect the structure, not accept the category.

Inspect. Assess. Apply the code.

AWW is auditing all 49 private gender clinics in Australia for compliance with Australian Consumer Law and National Law informed consent standards. Every clinic audited to date has failed to meet these standards.
See https://www.aww.org.au/informed-consent

Anyone who has ever sat in a doctor’s surgery understands a fundamental truth of medicine: you get a diagnosis before you get a treatment plan. The doctor listens, examines, investigates, considers differential diagnoses, weighs evidence, and only then selects from a range of reasonable options. In the past, gender medicine offered watchful waiting, psychological support, or medical intervention. This is not a specific treatment. It is a process. It is the standard medical model that has safeguarded patients for generations.

In gender medicine, this process has been quietly replaced. What is now called the “Gender Affirming Care” (GAC) model is provided in the gender clinics as a competing version of the standard medical process. It structurally privileges a predetermined direction: affirmation leading to social transition, hormones, and surgery, dressed up as a clinical framework. One treatment option replacing others; watchful waiting, exploratory therapy or mental health support for example, has been elevated into the entire process itself. The destination is selected before the journey begins. This is not a minor variation in practice. It is a profound category error, one my organisation, Active Watchful Waiting (AWW), is trying to communicate to AHPRA.

Table 1 from Regulatory Concerns AHPRA-ACON found on

https://www.aww.org.au/health-professionals

I looked at the Medical Board of Australia’s ‘Good Medical Practice: A Code of Conduct for Doctors in Australia’ (October 2020), and found it built around process, not outcomes. It governs how doctors make decisions: how they gather and weigh information, how they obtain informed consent, how they balance benefits and harms, and how they work within the limits of evidence. Section 3.2.7 requires a “reasonable expectation of clinical efficacy and benefit” before recommending treatment. Section 4.5 demands comprehensive informed consent that includes evidence uncertainty, alternatives, and material risks. These are not optional. They are the architecture of safe, ethical medicine, and they’re ignored in the ‘gender affirming care model’.

I submitted a formal compliance assessment and detailed matrix to AHPRA and the Medical Board on 20 May 2026. It shows that gender affirming care, as a model and as currently practiced in Australia, systematically violates at least ten sections of the Code. The matrix compares the two approaches side-by-side. Under the Standard Medical Model, treatment recommendations allow for input from multiple high-quality systematic reviews (Cass Review 2024, University of York reviews, US HHS 2025 review). Interventions are only offered when there is reasonable evidence of benefit. Full disclosure of uncertainty, harms (sterility, sexual dysfunction, bone health impacts, lifelong medical dependency), and alternatives (including psycho-therapeutic approaches) is mandatory. Systematic outcome monitoring is standard.

See Compliance Matrix on

https://www.aww.org.au/health-professionals

The GAC model, and the clinics that follow it, fail these tests because of a structural design that mistakes an outcome, gender affirming treatment, for the entire diagnostic process. It dismisses all other treatments as mere options. It privileges affirmation of the patient’s self-identified gender as the starting point and primary goal. This pre-committed pathway leads to reliance on transgender advocacy-aligned guidelines while sidelining contrary systematic evidence of poor-quality data, lack of randomised controlled trials, unknown long-term outcomes, and persistent uncertainty about benefit. Harms are often minimised. Interventions are frequently framed as “life-saving” or “medically necessary” without robust evidence. Informed consent is routinely incomplete. Professional disagreement is not disclosed. These are not isolated failures. They are the predictable consequences of substituting a predetermined protocol for open-ended clinical reasoning.

To understand the inversion, consider an analogy. Imagine oncology adopting a “Chemotherapy Affirming Model.” A patient presents with fatigue, weight loss, and a cough. The clinician affirms the patient’s belief that they have cancer, initiates chemotherapy immediately because “delay causes psychological harm,” and skips biopsy or staging on the grounds that questioning the patient’s self-diagnosis would be invalidating. No responsible oncologist would accept this. The obvious objection, that cancer can be confirmed by biopsy while gender distress cannot. But that only sharpens the point: the less certain the diagnosis, the greater the obligation to investigate before acting irreversibly. It does not merely violate good medical practice in its details; it abolishes the foundational requirement of diagnostic humility*: the ability to approach patient encounters with curiosity rather than conclusive assumptions, before applying irreversible intervention.

The same category error exists in gender medicine. It is important to be precise. “Gender affirming care” as a value is uncontroversial and entirely consistent with good medical practice: treating patients with dignity and respect, and refusing to shame or dismiss their distress. Compassionate, respectful clinical manner is a baseline expectation. The problem lies with the “Gender Affirming Care Model” as a clinical protocol. Conflating compassionate manner with a pre-selected treatment pathway is exactly how the category error became institutionalised. Affirming a patient’s feelings is humane. Pre-selecting irreversible medical interventions as the default response to gender distress, before proper diagnostic assessment, is not.

The compliance matrix submitted to AHPRA sets out the real-world consequences. It demonstrates breaches of core requirements around evidence-based decision-making (3.2.7), informed consent (4.5), balance of benefit and harm (3.2.4), honesty and trustworthiness (2.1), and avoidance of exploitation of vulnerability (10.7.3). These violations flow directly from the model’s structural substitution of outcome for process.

AHPRA regulates process, not specific clinical decisions. Its role is to ensure doctors follow the disciplined framework the Code demands in every other area of medicine. By allowing a model that structurally displaces that framework, the regulator risks undermining the very standards it exists to uphold. The Standard Medical Model does not prohibit transition for carefully selected adults after thorough assessment. It simply insists that any intervention must emerge from proper process, robust evidence, and genuine informed consent, especially when the patients are minors facing permanent changes.

The category error is plain: gender affirming care is not a flawed version of the standard model. It is the abolition of the standard model’s most important feature: diagnostic humility before irreversible action. Restoring the integrity of medical process is not a culture-war issue. It is a patient-safety imperative. Vulnerable young people and their families deserve the same rigorous, evidence-based, ethically sound decision-making process required everywhere else in medicine.

My audits of Australian private gender clinics suggest this is not a theoretical concern. The category error is operational. Across clinic materials, the affirmation model is reflected in service design, public claims, consent omissions, risk minimisation, and the absence of genuinely visible alternative pathways. Clinics present gender-affirming care as safe, evidence-based and clinically standard, while failing to disclose material risks, evidence limitations, long-term uncertainty, fertility consequences, minor-specific safeguards, and non-medical alternatives. That pattern is why my organisation has submitted compliance assessments to regulators under Australian Consumer Law, the Health Practitioner Regulation National Law, the Medical Board’s Code of Conduct, and AusPATH’s own framework.

AHPRA now has the submission and matrix before it. The question is whether it will continue to treat the GAC model as “the standard approach to gender medicine”, or recognise it for what it is: a protocol that replaces open clinical reasoning with a predetermined destination. Professional standards and patient safety require AHPRA to recognise the category error.

Appendix:

• See Sky News talking about our complaints “Misleading advertising’: ACON clinic hit with complaints: https://www.skynews.com.au/opinion/misleading-advertising-acon-clinic-hit-with-complaints/video/5c7ad0016a9fa892e8c187ff49fb6e43

• Our work also made it to the front page of The Australian 29 May: https://archive.md/jHb0y

  

• Audits, letters etc will be uploaded to https://www.aww.org.au/informed-consent

Endnote: * Diagnostic humility is a clinical approach where a practitioner continuously acknowledges the limits of their knowledge, questions their initial conclusions, and remains open to contradictory information. It serves as a vital safeguard against cognitive bias and premature conclusions.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10838525/

A 2024 study on diagnostic communication with older adults found that when clinicians approached encounters with curiosity rather than conclusion, diagnostic accuracy improved and unnecessary testing decreased (Tran et al., 2024). Clinicians who embrace diagnostic humility demonstrate stronger reasoning, engage more deeply with patient narratives, and are less likely to commit premature closure (Vally et al., 2023).

Share AWW’s Substack

Please consider donating to support this work. The handful of audits we've completed so far have taken months of full-time, unpaid effort - each complaint letter, matrix and follow-up is painstaking, evidence-by-evidence work. It matters because it documents the unlawful conduct of private gender clinics and holds the regulators to account for failing in their duty to enforce the law and the medical codes of practice. While we've suspended paid work to do it, your help means we can keep going.

Go to https://www.indefenceofchildren.org/ and click on Donation.

In a free society, adults may believe they are wolves. They may also believe they are dragons, demons, angels, elves, foxes, or spiritually misunderstood woodland creatures. They may wear ears, write poetry about their theriotype, and explain at dinner parties that their inner self is not, strictly speaking, human. That is their business.

My interest begins when a registered psychology clinic takes those beliefs, wraps them in therapeutic authority, and offers the result to consumers as “affirming, scientifically-informed clinical support.”

That is the actual wording on the Adult Gender & Sexology Clinic page of

King Street Psychology Clinic

in Sydney. The service is offered to people who identify as otherkin or therians, and to the parents and partners of those with “non-human feelings or identities.” The phrase doing the heavy lifting is scientifically-informed.

https://kingstreetpsychologyclinic.com.au/adult-gender-and-sexology-clinic#othersupport

Informed by what science?

There is no diagnostic category for otherkin identity in DSM-5-TR or ICD-11. There are no peer-reviewed trials demonstrating that affirming someone’s non-human identity improves outcomes. There are no clinical guidelines. There is no evidence that telling a man identifying as a wolf he is valid is safer than asking why he feels unable to live as a human.

“Scientifically-informed” is doing what it usually does in these settings: gesturing at a body of evidence the consumer is invited to assume exists somewhere behind the curtain.

The modern identity marketplace has discovered a marvellous recipe. Take a self-concept. Add authenticity. Add disclosure. Add community belonging. Add non-pathologising. Add affirming. Place it on a professional website. Sprinkle with scientifically-informed. Wait for the vulnerable consumer to infer the science.

Woman to man. Man to woman. Man to non-binary. Man to wolf. Man to dragon.

The category changes. The therapeutic language is oddly portable.

Once identity becomes the thing to be affirmed rather than the thing to be assessed, the model can travel almost anywhere. A person says, “I feel I am not what my body says I am.” The clinician says, “How brave.” The website says, “Scientifically-informed.” The parent says, “Is this evidence-based?” The invoice says, “Thank you for your payment.”

Insert distress. Select identity. Receive affirmation. Science pending.

Clinic intake form Question 1: Do you identify as human? ☐ Yes ☐ No ☐ It is harmful to ask

The point is not that people with unusual identities should be mocked. Many are likely vulnerable. Some are experimenting. Some are coping with loneliness, autism, dissociation, trauma, or developmental distress. Some are immersed in online subcultures that have given them their first language for suffering. Some are eccentric adults with unusual spiritual beliefs who would benefit from ordinary counselling and a safe place to talk.

You cannot know which until you assess.

That is the problem with public promises to be affirming and non-pathologising before the person has walked through the door. The conclusion has been written before the assessment begins. And once that happens, the service starts to look less like psychology and more like a vending machine with a clinical logo.

Vulnerable people deserve clinicians who can sit with complexity, not baptise every self-concept as authentic. They deserve careful differential thinking, not a service menu that places gender identity, sexual identity, and non-human identity along the same affirming conveyor belt.

And consumers deserve truthful advertising.

If King Street Psychology Clinic wants to offer general counselling to people experiencing unusual identity beliefs, it can say so. If it wants to support families dealing with distress, secrecy, neurodivergence, or subculture conflict, it can say so. But if it wants to advertise affirming, scientifically-informed clinical support for people who identify as wolves, demons, dragons, or angels, the public is entitled to ask a very boring, very Australian question.

Where is the science?

Because “scientifically-informed” is not a magic spell.

And even dragons should not be sold ‘evidence-based’ snake oil.

Article born of WTF irritation whilst doing the private gender clinic audits - see

https://www.aww.org.au/informed-consent

This is the third in a series examining systematic consumer-protection audits of Australian gender clinics. Links to the earlier pieces are at the end.

There is a basic rule in public life: the referee should not be trained by one of the teams.

In Australia’s most contested area of medicine – gender-affirming treatment for children and young people-that principle has been quietly abandoned.

Freedom of Information material cited in a new regulatory accountability schedule raises a serious question for parents, doctors, MPs and taxpayers: what happens when the organisation helping shape a national health regulator’s approach also operates a clinic subject to that regulator’s oversight?

That is the central issue I raised with AHPRA and the ACCC in providing Supplementary Schedule B (i) of Active Watchful Waiting’s compliance assessment into Kaleido Health Centre, an ACON-operated service offering gender-affirming healthcare. I do not argue in that document that LGBTQ health initiatives are illegitimate. Nor do I argue that gender-affirming care should be banned. The narrower and more difficult claim is one of governance: regulatory independence requires separation between those who influence standards and those who are assessed under them. That is a governance question, not a culture-war question.

That distinction matters. It wasn’t my intent to make the document a culture-war pamphlet dressed up as compliance work. My goal is a case study in institutional accountability: I am investigating a regulator, an advocacy organisation, a taxpayer-funded clinic, vulnerable patients, and public-facing medical claims said to omit material risks.

The allegation I make is simple enough for any parent to understand: the regulator watching over a clinic treating minors has partnered with the organisation operating that clinic.

The partnership that should alarm Parliament

AHPRA - the Australian Health Practitioner Regulation Agency - is not a minor bureaucratic agency. It works with the National Boards to regulate health practitioners and health-service advertising under the National Law. Its public function is to protect the public, uphold professional standards, and maintain trust in regulated healthcare.

On its own website, AHPRA states that it is committed to being a “safe regulator” for LGBTIQA+ practitioners and to contributing to health equity. It says it is doing this by, among other things, embedding Rainbow Health Australia’s standards in the “processes, policies and culture of the National Scheme” and working with Pride in Diversity to participate in the Australian Workplace Equality Index. ( AHPRA)(ii)

That public statement is significant because Pride in Diversity and Pride in Health + Wellbeing sit within ACON’s Pride Inclusion Programs. ACON describes Pride in Diversity as the national not-for-profit employer support program for LGBTQ workplace inclusion and publisher of the Australian Workplace Equality Index. It describes Pride in Health + Wellbeing as a national membership program supporting LGBTQ-inclusive service delivery across the health and wellbeing sector, including government departments, hospitals, GPs, mental health, drug and alcohol services, disability services and other providers across the lifespan. (ACON) (iii)

There is nothing inherently wrong with a regulator listening to minority communities. On the contrary, regulators should understand the populations they serve. But Schedule B argues that this relationship goes further than consultation. It says Freedom of Information (FOI) documents reveal AHPRA’s “systematic embedding” of ACON positions into regulatory functions. According to the schedule, a 7 February 2024 AHPRA National Executive agenda paper, marked “In confidence”, referred to partnering with organisations such as ACON’s Pride in Health and Wellbeing and stated that “Strategy and Policy” would lead work on access to the National Scheme, external engagement initiatives and National Board portfolios. It also stated that the LGBTIQA+ strategy would include reforms of “people policies and regulatory processes” over a three-to-five-year horizon.

Those words are not about morning tea pronouns or rainbow lanyards. “Regulatory processes” means the machinery by which standards, complaints, risk settings, and professional expectations are shaped.

The schedule also cites a 25 July 2025 letter from AHPRA CEO Justin Untersteiner stating that AHPRA’s engagement with ACON reflects efforts to ensure “lived experiences and expectations” are reflected in “the way we regulate” and fulfill public-safety functions. The Australian has separately reported on FOI documents and correspondence suggesting AHPRA’s relationship with ACON and Rainbow Health Australia extended to the way it regulates health practitioners, and that 46 medical professionals had warned the relationship risked positioning AHPRA as a partisan actor in a contested area of clinical practice. (The Australian)

This is the point at which MPs should stop thinking about “inclusion training” and start thinking about institutional design.

If ACON were merely one stakeholder among many, the concern would be smaller. But ACON is not only an advocacy organisation. It is also connected to service delivery.

From advocacy to service delivery

ACON’s own site lists Kaleido Health Centre among its service links. (ACON) AWW’s ACCC complaint states that Kaleido Health Centre operates as a trading name of ACON Health Centre Limited, ABN 52 676 923 587, providing GP-led gender-affirming hormone therapy, mental health services, social transition support, surgical referral support and related services.

Schedule A of the same material addresses the corporate structure. It records that Kaleido’s Q&A page represented Kaleido Health as “a separate entity to ACON, with its own CEO and its own Board of Directors,” while public corporate records and Kaleido’s own website footer identify “Kaleido Health Centre” as a trading name of ACON Health Centre Limited. The schedule says the relevant distinction is not whether separate branding is lawful – of course it is – but whether consumers are misled about independence, governance, complaints pathways and accountability.

That matters because consumers do not choose healthcare in the abstract. They choose a provider, a governance structure, a complaints pathway, and an implied trust relationship. If a clinic is presented as independent when it is in fact closely integrated into a broader advocacy and health-service group, that is material information. Schedule A argues that a reasonable consumer may form different expectations about privacy, clinical governance, oversight and accountability if told the clinic is separate from ACON.

Now combine that with Schedule B.

ACON influences AHPRA’s approach through Pride in Diversity, Pride in Health + Wellbeing, AWEI and related frameworks. ACON Health Centre Limited operates Kaleido. AHPRA regulates practitioners and health-service advertising. Kaleido is the clinic whose public materials are now alleged to contain serious consumer-law and professional-standards deficiencies.

That is the circle.

ACON influences the regulator.

The regulator sets expectations and investigates complaints.

The same ACON-linked structure operates a clinic subject to those expectations.

The clinic is then assessed for possible failures that the regulator should, in principle, detect or address.

Schedule B calls this a “circular accountability problem”: the organisation that influences the regulator also operates clinics subject to that regulation, compromising independent oversight and public confidence.

A mining company shaping environmental inspection rules for its own mine would be obvious. A bank shaping prudential oversight of its own products would be obvious. A pharmaceutical company training the drug regulator on how to view its therapeutic class would be obvious. The question is why this is less obvious when the subject is gender medicine.

What Kaleido allegedly failed to disclose

The governance issue would be concerning even if Kaleido’s public materials were exemplary. But AWW’s complaint says they were not.

The ACCC complaint alleges that Kaleido’s public website made unqualified claims about “evidence-based care” and “safe” services while omitting material information required for consumer decision-making. Most critically, it says Kaleido confirmed via a Q&A page - allegedly not accessible through standard website navigation - that it treats “people of all ages, including young people and those under 18,” while public service pages provided no information about age limits, parental consent requirements, minor-specific protocols, or court processes.

The complaint alleges a series of Australian Consumer Law concerns: hidden age eligibility information; unqualified evidence-based claims without disclosure of evidence uncertainty; complete absence of risk disclosure despite hormone therapy being offered; no disclosure of irreversible effects; fertility impacts not disclosed while fertility preservation was listed only as a future service; no disclosure of high progression rates from initial intervention to irreversible pathways; reliance on AusPATH alignment without disclosing limitations; and no parental-consent or minor-specific safeguards despite services including minors.

A separate AHPRA notification alleges that Kaleido’s advertising used reassurance-oriented language - “safe”, “high-quality”, “best-practice”, “evidence-based”, “developmentally appropriate” - while systematically omitting material risk information, evidence limitations, fertility implications, irreversibility warnings, treatment alternatives and minor-specific safeguards.

This is the crucial point for parents: the alleged failure is not that Kaleido publicly advocated gender-affirming care. It is that, according to the audit, the website offered reassurance without matching disclosure.

A public-facing claim of “safe” care means something different when the patient is a competent adult seeking routine, reversible care. It means something else when the service involves minors, cross-sex hormones, fertility implications, sexual development, irreversible bodily changes, and disputed evidence for long-term outcomes.

Health professionals understand this distinction immediately. Informed consent is not a vibe. It is not a rainbow slogan. It is the provision of understandable, material information before consent is sought.

The Medical Board’s Good Medical Practice Code requires doctors to discuss condition, management options, potential benefits and harms, and material risks. Schedule B quotes the Code’s informed-consent language: consent is a voluntary decision made with knowledge and understanding of benefits and risks, and good practice includes providing information patients can understand before asking for consent. It also highlights the heightened duties owed to children and young people, including placing their interests first and considering capacity for decision-making and consent.

That is why the omission of minor-specific protocols is not a technicality. It goes to the heart of paediatric medical ethics.

The minors question

The most politically explosive part of the material is not corporate structure. It is minors.

AWW’s complaint says the hidden Q&A page confirmed Kaleido treats “people of all ages, including young people and those under 18,” but that publicly accessible Gender Affirmation and Child, Family & Youth pages did not disclose age limits, parental or guardian consent requirements, capacity assessment processes, age-differentiated clinical pathways, or court processes where disputes arise.

For parents, that is the question that cuts through the jargon.

Can a parent visiting a government-funded clinic’s website easily determine whether their child is eligible for gender-affirming hormone therapy? Can they see whether parental consent is required? Can they see what safeguards apply if a child has trauma, autism, depression, anxiety, family conflict, or other complicating factors? Can they see whether fertility, sexual function, bone density, cardiovascular risk, irreversibility, regret, detransition, or long-term uncertainty are disclosed before contact with the clinic?

If the answer is no, the problem is not “debate.” The problem is consumer protection.

AWW’s Substack article on the Kaleido audit puts the same point starkly: people considering hormone therapy, surgery referrals and other interventions “cannot find basic safety information anywhere on the clinic’s public website,” while the website advertises services as “safe,” “evidence-based,” and “high-quality.” (ACON’s Gender Clinic fails to Disclose Medical Risks (AWW substack)

The AHPRA notification goes further, identifying public-interest concerns including vulnerable patients, minor involvement, irreversible interventions, evidence uncertainty, and informed-consent integrity. It says the clinic treats minors but provides no public information about parental consent requirements, legal safeguards or age-differentiated protocols, and that treatments advertised include interventions with permanent effects such as infertility and sexual-function changes.

For MPs, the question is obvious: what conditions attach to public funding when a health service advertises interventions to vulnerable populations, including minors?

For doctors, the question is equally obvious: would similar omissions be tolerated in any other field involving fertility, sexual development, cardiovascular risk and permanent bodily change?

The evidence problem

The Schedule B material also places Kaleido’s website claims inside the broader evidence debate. The contrast table in Schedule B compares what it calls the standard medical model - formal assessment, evidence-quality disclosure, risk-benefit discussion, alternatives, heightened duties for minors and ongoing monitoring - with the gender-affirming care model as described in clinic materials and WPATH-aligned approaches. The table argues that standard medical practice requires disclosure of risks, uncertainties, alternatives and evidence quality, especially where minors are involved.

This matters because “evidence-based” is not a decorative phrase. It is a claim that carries weight with consumers.

AWW’s companion article on the Medical Board’s Code states that the Cass Review, University of York systematic reviews and 2025 US Health and Human Services evidence review reached similar conclusions about weak or very-low certainty evidence for gender medical interventions in minors, with persistent uncertainty about benefit. (

The Compliance Gap: Gender Medicine and the Medical Board’s Code of Conduct (AWW substack)

The compliance matrix (v) supplied with the documents argues that a standard medical model reviews multiple systematic evidence sources, while the gender-affirming care model is said to rely primarily on advocacy-aligned guidelines and insufficiently engage with contrary systematic evidence.

For the full Compliance Matrix see footnotes

One need not accept every conclusion in AWW’s matrix to see the regulatory significance. If a contested medical field is marked by systematic reviews finding low-certainty evidence, then public claims of “evidence-based care” require care, qualification and context.

The same is true of “safe.” In ordinary consumer law, a business cannot create a reassuring overall impression while burying or omitting material risks. In health advertising, the stakes are higher.

The AWW complaint asks the ACCC to require Kaleido to add age eligibility, parental consent requirements and minor-specific protocols to publicly accessible pages; require comprehensive informed-consent information including risks, evidence uncertainty, irreversibility, fertility impacts, alternatives and progression rates; prohibit unqualified “evidence-based care” and “safe” claims without evidence limitations and treatment-risk disclosure; and correct corporate-structure representations about “separate entity” status.

These are not radical remedies. They are disclosure remedies.

The chilling effect on doctors

The structural risk here matters before any individual case. Even if every AHPRA decision were defensible on its own facts, the appearance of partiality corrodes trust. In regulation, perceived bias can be almost as damaging as actual bias, because compliance systems depend on confidence that the referee is independent.

Schedule B also alleges differential enforcement: AHPRA investigates or restricts doctors who express concerns about gender-affirming treatment, while dismissing complaints against doctors promoting it. As illustration, the document cites reported cases involving psychiatrists Andrew Amos and Jillian Spencer, and a dismissed complaint against Michelle Telfer, former head of the Royal Children’s Hospital Melbourne gender service, despite controversy and adverse judicial commentary.

The Australian has reported that AHPRA faced calls to sever ties with ACON after FOI material suggested its LGBTIQA+ strategy extended to regulatory functions, and that critics linked the issue to cases involving Andrew Amos and Jillian Spencer. (The Australian)

Whether or not one accepts the differential-enforcement reading of those specific cases, the structural concern stands on its own. If doctors believe the regulator is aligned with one side of a contested clinical debate, they may self-censor. If questioning evidence quality is perceived to risk investigation, while promoting contested interventions attracts institutional protection, the result is not better care. It is poorer medicine.

Medicine depends on dissent, audit, adverse-event reporting, and second opinions. It depends on the ability to say: “What is the evidence? What are the risks? What is the alternative? What happens if we wait? What happens if we are wrong?”

A regulator that chills those questions ceases to be a guardian of professional standards and becomes a guardian of orthodoxy.

That is precisely why the AHPRA–ACON relationship matters.

The taxpayer question

The public-interest dimension is unavoidable.

Kaleido is described in AWW’s materials and articles as a NSW government-funded LGBTQ+ health service run by ACON Health Centre Limited. (AWW Substack)

ACON’s broader Pride Inclusion ecosystem includes membership, bench-marking, training and awards programs aimed at embedding LGBTQ-inclusive practice across workplaces, sporting organisations, government departments, hospitals, GPs and health services. (ACON)

Again, inclusion is not the problem. The problem is the collapse of boundaries.

An advocacy organisation may advocate. A service provider may deliver services. A regulator may regulate. But when the same advocacy ecosystem influences regulatory processes, operates or is connected to clinics, and shapes institutional expectations in the very field under review, public accountability becomes blurred.

Who is responsible if a parent says they were misled?

The clinic?
The corporate group?
The regulator?
The government funder?
The professional board?
The inclusion framework that shaped the regulator’s settings?

I don’t know. But my guess is that circular accountability is accountability that always points elsewhere.

What Parliament should ask

Schedule B is written for parliamentary committees, health ministers, enforcement authorities, journalists and health professionals concerned about regulatory independence. Its significance lies in the questions it makes unavoidable.

Parliament should ask AHPRA:

• Did any ACON-linked training, accreditation, bench-marking or consultancy influence complaint handling, professional standards interpretation, advertising guidance or practitioner conduct expectations in gender medicine?

• What governance safeguards exist to prevent advocacy partners from shaping regulatory processes affecting their own service-delivery arms?

• How does AHPRA manage apprehended bias when considering complaints involving ACON-operated or ACON-linked services?

• Has AHPRA independently reviewed whether participation in Pride in Diversity, AWEI, Pride in Health + Wellbeing or Rainbow Tick frameworks is appropriate for a national health regulator?

• Why were alleged omissions on publicly accessible gender-clinic websites - including risk disclosure, fertility, irreversibility and minor safeguards - not identified through routine advertising oversight?

Parliament should ask NSW Health:

• What funding conditions apply to Kaleido and similar services concerning advertising accuracy, informed-consent transparency, and public disclosure of risks?

• Are government-funded services required to disclose age eligibility, parental consent processes, evidence uncertainty and fertility implications on public-facing pages before vulnerable consumers make contact?

• What independent clinical governance sits above services operating within advocacy-linked structures?

Parliament should ask the ACCC and AHPRA:

• When a clinic advertises “safe” and “evidence-based” gender-affirming services but allegedly omits material risk information, which regulator acts first?

• If both regulators have diversity or inclusion partnerships with the same advocacy ecosystem, how is public confidence preserved?

This is not an argument against dignity

The predictable response will be to cast any scrutiny as hostility toward LGBTQ people. That would be a mistake.

Vulnerable people deserve compassionate healthcare. Trans-identified adults deserve dignity, respect and competent care. Young people in distress deserve careful assessment, not slogans. Parents deserve truthful information. Doctors deserve freedom to practise evidence-based medicine without fear. Taxpayers deserve to know that publicly funded services are regulated independently.

The strongest version of LGBTQ health equity is not one that exempts services from ordinary standards. It is one that insists those standards apply with special seriousness because the population served is vulnerable.

Disclosure is not discrimination.
Risk information is not stigma.
Evidence scrutiny is not hate.
Regulatory independence is not bigotry.

It is the minimum condition of public trust.

The public-interest conclusion

The Kaleido compliance assessment is not merely about one clinic’s website. It is about what happens when health regulation, advocacy, public funding and contested medicine become entangled.

AWW’s Schedule B argues that the AHPRA–ACON relationship creates a structural conflict of interest: the organisation influencing the regulator also operates clinics subject to that regulatory environment. The accompanying ACCC and AHPRA materials allege that Kaleido’s public-facing materials omitted material risk information, evidence limitations, fertility implications, irreversibility warnings, treatment alternatives and minor-specific safeguards while using reassuring claims such as “safe,” “evidence-based,” “best-practice” and “developmentally appropriate.”

Those claims now require independent scrutiny.

Not by ACON.
Not by a regulator shaped by ACON’s frameworks.
Not by internal diversity committees.
Not by activists on either side.
By independent bodies answerable to the public.

Parents do not need another statement about inclusion. They need to know whether clinics treating minors are disclosing risks. Doctors do not need ideological instruction from regulators. They need assurance that evidence-based dissent will not be punished. MPs do not need another stakeholder round table. They need to determine whether public regulators are maintaining independence from the organisations they oversee. Taxpayers do not need branding. They need accountability.

The question at the heart of Schedule B is therefore not whether ACON has done good work historically, nor whether LGBTQ patients deserve safe and respectful healthcare. They do.

The question is whether Australia’s medical regulator can credibly oversee gender medicine while partnering with an advocacy ecosystem that shapes its regulatory processes and is linked to clinics operating in that same field.

Until that question is answered, the public is entitled to ask whether the watchdog is still watching – or whether it has joined the kennel.

Status of complaints

A formal complaint regarding Kaleido Health Centre has been lodged with the Australian Competition and Consumer Commission (ACCC Reference: REF4733131) by Active Watchful Waiting Inc. A parallel notification to AHPRA concerning the same clinic’s advertising and informed-consent has been sent, response from Criminal Offences team is pending. This article summarises material drawn from those submissions and their supplementary schedules; the underlying audit and schedules are available at https://www.aww.org.au/informed-consent

Contact Catherine Karena – contact@aww.org.au

(i)Supplementary documents A and B:https://059a0850-e44d-4bff-96fd-7905fa1fe157.filesusr.com/ugd/0bf645_4940af4e18f64805951a0d55877f59d9.pdf

(ii) https://www.ahpra.gov.au/Resources/LGBTIQA-communities.aspx/

(iii) https://www.acon.org.au/what-we-are-here-for/pride-inclusion-programs/

(iv)Download full compliance matrix: https://www.aww.org.au/_files/ugd/0bf645_a5f05ab107b04a929b3408667672094e.pdf

Links to earlier pieces in the series:
https://indefenseofchildren.substack.com/p/acons-gender-clinic-fails-to-disclose
https://indefenseofchildren.substack.com/p/the-compliance-gap-gender-medicine

The Story

Two independent compliance reviews have uncovered serious failures at Kaleido Health Centre, a NSW government-funded LGBTQ+ health service run by ACON Health Centre Ltd, which is advertising gender-affirming medical interventions without disclosing ANY of the known material risks to consumers.

Following a 59-page audit/compliance review submitted to the ACCC documenting non-compliance with Australian Consumer Law sections 18 and 29, and AusPATH 2025 Benchmark Comparison. I recently also conducted a parallel compliance review against the advertising requirements for regulated health services under section 133 of the National Law. I’ll be submitting that as supplementary document C to add to appendix documents I submitted on the regulatory capture concerns.

The initial ACCC audit assessed:

1. Whether publicly available website materials contain representations or omissions that are, or are likely to be, misleading or deceptive (ACL s18) or false/misleading in specific respects (ACL s29) regarding gender-affirming services.

2. The adequacy of pre-treatment public information for informed consumer decision-making, with particular attention to age eligibility, risks, benefits, evidence quality, irreversibility, fertility, alternatives, and minor-specific considerations.

3. Factual, evidence-based findings suitable for regulatory consideration.

Using those findings, I found the AHPRA compliance review with regards to medical centre advertising found that people considering hormone therapy, surgery referrals, and other medical interventions cannot find basic safety information anywhere on the clinic’s public website.

This is a textbook case of misleading by omission. The website prominently advertises services as ‘safe,’ ‘evidence-based,’ and ‘high-quality’ - but doesn’t tell consumers about blood clots, cardiovascular risks, fertility impacts, or that many effects are permanent and irreversible.

Kaleido Health Centre is operated by ACON Health Centre Limited, a major LGBTQ+ advocacy organisation that receives NSW government funding.

WHAT CONSUMERS AREN’T BEING TOLD

The audit found ZERO disclosure of:

🔗

See slide show of 39 Risks

:👇

Screen shot of first slide, see slide show of the 30+ concerns:

https://tinyurl.com/MaterialRisks

THE PUBLIC PROTECTION FAILURE

Under Australian health practitioner law, medical services advertising must not mislead consumers through omission. The law specifically identifies “minimising, underplaying or under-representing risk” as one of the strongest grounds for regulatory breach.

What the AHPRA compliance review found:
✗ Benefits prominently advertised (”safe,” “evidence-based,” “affirm identities safely and confidently”)

✗ Risks completely absent (not under-disclosed - entirely missing)

✗ Creates categorical imbalance (benefits maximally promoted, risks entirely suppressed) - benefits scored 5/5 for prominence, risks scored 0/5

This isn’t a case of inadequate disclosure, it’s systematic omission across every category - risks, evidence quality, alternatives, limitations, uncertainties. A reasonable person reviewing this website would conclude that gender-affirming care is straightforward, safe, effective medical treatment. They wouldn’t understand they’re considering interventions with serious, potentially life-threatening risks.

REAL-WORLD IMPACT: WHO IS AFFECTED

1. Adults Making High-Stakes Medical Decisions
Adults considering hormone therapy cannot find information about:

• Blood clot risks (venous thromboembolism can be fatal)

• Cardiovascular disease risk

• Permanent fertility impacts

• Irreversible physical changes

• Monitoring requirements (lifelong blood tests, health surveillance)

These aren’t minor side effects, these are serious medical risks that could affect someone’s life expectancy, fertility, and long-term health. People have the right to know this information BEFORE they make treatment decisions.

2. Families with Gender-Questioning Youth
Kaleido operates a “Child, Family & Youth Health” service alongside its gender affirmation services. In the ACL content compliance audit’s finding 9:

“Clinic confirms via hidden Q&A page that it treats ‘people of all ages, including young people and those under 18’, yet provides zero information about parental consent requirements, minor-specific assessment protocols, age-differentiated risks, or Family Court processes for capacity/treatment disputes.”

On the entire Kaleido Health Centre’s website audit found the following:

Families cannot determine from the public website whether their teenager can access medical interventions, what consent is required, or what the legal framework is. This creates serious ambiguity for parents trying to understand their options and responsibilities.

THE EVIDENCE QUALITY OMISSION

While Kaleido advertises services as “evidence-based,” the audit found the website makes no mention of:

• The Cass Review (2024) - UK’s major systematic review finding “remarkably weak” evidence for youth gender medicine

• U.S. HHS “Treatment for Pediatric Gender Dysphoria” 2025 -Found very low certainty of long-term benefits; sparse and weak harms reporting and highlighted methodological limitations

• International restrictions - Sweden, Finland, Norway, and the UK have all restricted or stopped routine youth hormone prescribing

• Evidence quality debates - ongoing professional disagreement about effectiveness and safety

• Long-term outcome data gaps - limited follow-up studies on hormone therapy outcomes

“Using ‘evidence-based’ as marketing language without explaining the actual evidence or its limitations is exactly what AHPRA prohibits.”

THE REGULATORY BREACHES
The audit documents violations of Section 133 of the Health Practitioner Regulation National Law - Australia’s national framework for health service advertising.

Increased maximum penalty for advertising offences
In 2022, the National Law was amended and one of the changes was to increase the maximum penalty for advertising offences. For an individual, the maximum financial penalty per offence increased from $5,000 to $60,000, and for a body corporate the maximum financial penalty per offence increased from $10,000 to $120,000. The process for managing advertising breaches under the National Law is set out in section 1.3 of the guidelines.

https://www.ahpra.gov.au/Resources/Advertising-hub/Advertising-guidelines-and-other-guidance/Advertising-guidelines.aspx

Section 133 violations carry maximum penalties of $60,000 (individual) or $120,000 (body corporate) per offence. AHPRA’s typical enforcement process begins with a compliance notice providing opportunity to remediate, with prosecution proceedings following if non-compliance continues.

THE INSTITUTIONAL CONFLICT

Both regulatory agencies receiving these complaints have institutional relationships with ACON:

• Australian Competition and Consumer Commission (ACCC):
  Achieved Bronze tier status in ACON’s Australian Workplace Equality Index (AWEI)

• Source: ACCC media update,

  https://www.accc.gov.au/about-us/news/media-updates/accc-and-aer-achieve-awei-bronze-tier-status

• AWEI is a workplace inclusion benchmarking program operated by ACON

Australian Health Practitioner Regulation Agency (AHPRA):

• In January 2025, AHPRA’s Board and CEO received advice regarding “Pride in Diversity (PID), Australian Workplace Equality Index (AWEI), Rainbow Tick, and AIDS Council for New South Wales (ACON)”

• Source: AHPRA FOI Disclosure Log, Request 46884, 29 January 2025

• https://www.ahpra.gov.au/About-Ahpra/Privacy-Freedom-of-information-and-Information-publication-scheme/Freedom-of-Information/Disclosure-Log.aspx

• This advice was sought in January 2025, 16 months before these complaints were filed. Since then, Active Watchful Waiting has conducted 16 private gender clinic audits across Australia, all rated Seriously Deficient, with 49 ACCC complaints planned. Both agencies tasked with enforcing consumer and health advertising law against these clinics are AWEI members.

While AWEI participation relates to workplace inclusion practices rather than regulatory enforcement functions, these institutional relationships create a perception of conflict when the same agencies are tasked with regulating ACON’s health services.

I am not alleging that AWEI membership has influenced the handling of these specific complaints. However, the appearance of conflict is significant enough to warrant:

1. ICAC Referral - Assessment of whether institutional relationships between regulators and regulated entities create conflicts requiring independent oversight mechanisms

2. Ministerial Escalation - Request for NSW Minister to ensure government-funded health services are subject to independent compliance review where perception of regulatory conflict exists

3. Public Transparency - Media documentation of all regulatory pathways to ensure accountability

The dual regulatory submission (ACCC + AHPRA) establishes the compliance concerns through appropriate channels. Hopefully the parallel escalation pathways address the institutional conflict problem.

WHY THIS MATTERS

1. Informed Consent Cannot Exist Without Information
The clinic states it uses an “informed consent model” - but provides no material risk information publicly. Informed consent requires that people understand:

• What they’re consenting TO (the intervention)

• What the RISKS are (including serious/fatal risks)

• What the ALTERNATIVES are (including doing nothing)

• What is UNKNOWN (evidence gaps, long-term uncertainties)

Relevant AHPRA guidance:

“Advertisers should consider the overall impression of their advertising and how easily the audience can navigate and understand it.” (Guidelines, s4.1)

A website may raise National Law Section 133 concerns even if individual sentences are technically defensible, where the total impression omits material risks, uncertainty, eligibility limits, alternatives, or the limits of evidence.

In plain English, you cannot have informed consent when material information is systematically withheld.

2. Public Funding, Public Accountability
ACON receives NSW government funding to provide health services. These audits raises questions about:

• Oversight of government-funded health service advertising

• Consumer protection standards for funded organisations

• Whether funding conditions require compliant advertising practices

3. Sets Precedent for Sector-Wide Standards
If AHPRA finds serious breaches, it establishes what constitutes compliant gender clinic advertising. Other clinics would need to review their own practices.

My focus for these audits/compliance reviews were not about stopping gender-affirming care, it’s about requiring honest advertising. People considering these interventions deserve the same level of risk disclosure that’s standard for any other serious medical treatment.

WHAT HAPPENS NEXT

Three parallel regulatory pathways are now active:

Regulatory Enforcement Track:

• ACCC complaint submitted (Australian Consumer Law sections 18 and 29 violations)

• AHPRA complaint being submitted (National Law Section 133 violations)

• Standard enforcement process: compliance notice → remediation period → prosecution if non-compliance continues

• Timeline: Compliance notice typically within 2-3 months; remediation period 30-90 days; prosecution (if required) 6-12 months

Oversight Track:

• NSW Independent Commission Against Corruption (ICAC) referral

• Assessment of whether institutional relationships between regulators and regulated entities create perception of conflict requiring independent oversight

• Focus: ACCC and AHPRA’s AWEI membership while regulating ACON services

Political Accountability Track:

• NSW Minister for Health escalation

• Request for ministerial oversight ensuring government-funded health services comply with advertising law

• Request for clarification on how perception of regulatory conflict is managed

All submissions, regulatory responses, and outcomes will be documented publicly to ensure transparency.

About the Audits/Compliance Reviews
The audits were conducted by Catherine Anderson-Karena (usually shortened to Karena), Executive Director of Active Watchful Waiting Inc., a child protection and policy advocacy organisation. Karena is BBST-certified in software testing, an Association of Software Testing Instructor, who has 13 years of experience in software testing, compliance and quality assurance. Submitted materials have been reviewed by a former ACCC lawyer before submission—specifically to filter out over-statements or misapplications of the ACL and ensure accuracy through a consumer-law-expert lens. AWW wishes to clarify that while this input strengthens the submission’s quality,

AWW is not suggesting it confers any formal legal status on our findings.

About ACON
ACON is a major NSW LGBTQ+ health organisation operating health services including Kaleido Health Centre. It receives NSW government funding and positions itself as a leading provider of LGBTQ+ health services.

About AHPRA
The Australian Health Practitioner Regulation Agency (AHPRA) works with 15 National Boards to regulate health practitioners and health service advertising under the Health Practitioner Regulation National Law. Section 133 of the National Law prohibits false, misleading, or deceptive advertising of regulated health services.

MEDIA CONTACT

Catherine ‘Karena
Executive Director, Active Watchful Waiting Inc.
ABN: 31 199 239 644
Website:

aww.org.au

Contact: contact@aww.org.au

*Audit definition: in website/software testing it means a systematic, independent examination of records, content, processes, or controls to assess compliance or quality against a defined set of criteria (e.g., ISO principles, standards, or professional guidelines)

###

See https://www.aww.org.au/informed-consent for compliance audits

In October 2020, the Medical Board of Australia published its Good Medical Practice Code, setting clear standards for all registered doctors. Section 3.2.7 states that doctors must only recommend treatments “when there is an identified therapeutic need” and “a reasonable expectation of clinical efficacy and benefit for the patient.”

It’s a foundational principle: don’t prescribe interventions unless there’s good evidence they work.

Yet across Australia, gender clinics routinely recommend hormonal and surgical interventions for gender-distressed young people despite what multiple systematic reviews now make explicit: the evidence base is remarkably weak, long-term outcomes are unknown, and there is insufficient evidence to establish clinical efficacy.

The 2024 Cass Review in the UK, the University of York’s systematic evidence reviews, and the 2025 US Health and Human Services evidence review all reach strikingly similar conclusions: the quality of evidence supporting gender medical interventions in minors is poor to very low, with persistent uncertainty about benefit.

This raises an uncomfortable question: Is the Gender Affirming Care (GAC) model, as currently practised in Australia, compliant with the Medical Board’s own Code of Conduct?

A systematic assessment suggests it is not - and the compliance failures are serious, systemic, and span at least ten distinct areas of the Code.

Download full compliance matrix:

https://www.aww.org.au/_files/ugd/0bf645_a5f05ab107b04a929b3408667672094e.pdf

What We’re Comparing

This analysis examines two approaches to treating gender distress in young people:

The Standard Medical Model follows established medical principles: formal diagnosis, comprehensive risk-benefit disclosure, consideration of alternatives including psychological support, and treatment recommendations based on robust evidence of efficacy.

The Gender Affirming Care Model, as operationalised in current Australian practice, centres on affirming a young person’s self-declared gender identity and fast-tracking access to medical interventions - hormones and surgery - often with minimal psychological assessment and limited disclosure of evidence uncertainty.

The assessment draws on:

• The Medical Board’s Good Medical Practice Code (October 2020)

• Current systematic evidence reviews (Cass 2024, York, HHS 2025)

• An ongoing compliance audit of Australian private gender clinic websites (18 completed to date)

• Established medical ethics principles and regulatory standards

The comparison is not ideological. It’s a straightforward audit: which model complies with the standards all Australian doctors are required to meet?

The Two Serious Violations

Violation 1: Treatment Without Reasonable Expectation of Clinical Efficacy (Section 3.2.7)

The Code requires doctors to only recommend treatments when there is “a reasonable expectation of clinical efficacy and benefit.”

The GAC model recommends permanent, irreversible interventions - puberty blockers, cross-sex hormones, surgical removal of healthy tissue - despite:

• Multiple systematic reviews concluding the evidence is of poor quality

• No randomised controlled trials establishing benefit

• Unknown long-term outcomes

• Explicit statements that evidence is insufficient

The Cass Review states plainly: “The evidence base is remarkably weak.” The University of York systematic reviews repeatedly rate the evidence as “low” or “very low” certainty. The 2025 US Health and Human Services review finds insufficient evidence for benefits in adolescents.

This is not a marginal evidence gap. It is a foundational failure: doctors are recommending life-altering interventions without the evidence base the Code requires.

In standard medical practice, such evidence uncertainty would trigger caution. A doctor would not recommend permanent body modification to a teenager based on evidence rated “very low certainty.” They would not prescribe lifelong hormonal dependency when systematic reviews conclude the benefits are unknown.

Yet this is precisely what the GAC model does.

Compliance Assessment: Serious non-compliance. This violates one of medicine’s core principles.

Violation 2: Exploiting Patient Vulnerability Through Unsubstantiated Claims (Section 10.7.3)

The Code explicitly prohibits “exploiting patients’ vulnerability or fears about their future health, or raising unrealistic expectations.”

Yet GAC clinic websites and promotional materials routinely:

• Claim interventions prevent suicide (no robust evidence supports this)

• Exploit parental fear with framing such as “would you rather a dead daughter or a living son?”

• Promise authenticity, happiness, and living as one’s “true self”

• Present interventions as medically necessary when the evidence base is contested

A systematic audit of 49 Australian private gender clinic websites is revealing pervasive use of suicide-prevention framing without evidential support. The Cass Review explicitly addressed the lack of evidence linking gender interventions to suicide prevention, finding no reliable studies demonstrating that medical transition reduces suicide risk.

Parents of gender-distressed children are among the most vulnerable patients in medicine - desperate, frightened, and willing to do anything to help their child. The exploitation of that vulnerability through unsubstantiated claims is a serious breach of professional standards.

Consider what this looks like in practice: a parent, terrified their child might be suicidal, is told that hormones and surgery are medically necessary to prevent suicide. The claim is presented with the authority of medical expertise. The parent, understandably, consents. But the claim itself lacks robust evidential support.

This is not informed consent. It is coercion by fear.

Compliance Assessment: Serious non-compliance. This directly violates protections against exploitation of vulnerable patients.

Eight Additional Compliance Failures

Beyond these two serious violations, the GAC model demonstrates non-compliance across eight additional areas of the Code:

Informed Consent (Sections 4.5.1-2)

Code requirement: Provide information patients can understand, including benefits, risks, and alternatives, before asking for consent.

Standard Medical Model: Provides comprehensive information including evidence uncertainty, alternative approaches, permanence of effects, full scope of side effects including impacts on sexual function, lifelong medical dependency, and unknown long-term outcomes.

GAC Model: Often provides incomplete information. May omit evidence uncertainty, fail to discuss psycho-therapeutic alternatives, minimise permanence of effects, and inadequately explain sexual function impacts beyond fertility. The focus on “affirmation” can result in consent processes that frame alternatives as harmful or frame the intervention as medically necessary.

Evidence: Analysis of Australian gender clinic materials and clinic websites show limited disclosure of evidence quality concerns, minimal discussion of alternatives to medical intervention, and inadequate information about the permanence and scope of effects - particularly regarding sexual function, which extends far beyond fertility to include orgasmic capacity, sexual sensation, and relationship implications.

Compliance Assessment: Non-compliant. Informed consent requires understanding of “benefits and risks involved.” The GAC model’s incomplete disclosure fails this standard. Of particular concern: sexual function impacts are often not adequately disclosed, despite being permanent and life-altering.

Best Available Information (Section 3.2.6)

Code requirement: Provide treatment options based on the best available information.

Standard Medical Model: Reviews systematic evidence base; considers multiple high-quality systematic reviews (Cass, York, HHS 2025) and weighs their findings against single-source guidelines.

GAC Model: Relies primarily on single advocacy-aligned guideline (AusPATH 2025); dismisses or doesn’t engage with contrary systematic evidence from multiple independent reviews.

Evidence: The AusPATH guidelines, while citing evidence, do not adequately engage with the systematic reviews’ conclusions of uncertainty and poor evidence quality. Practitioners following GAC protocols often present the AusPATH position as settled medical consensus without acknowledging the contested evidence base.

Compliance Assessment: Non-compliant. The GAC model’s reliance on a single source while systematic reviews show uncertainty violates the requirement to base treatment on “best available information.”

Balance of Benefit and Harm (Section 3.2.4)

Code requirement: Consider the balance of benefit and harm in all clinical-management decisions.

Standard Medical Model: Explicitly weighs known harms - sterility, sexual dysfunction, bone health impacts, cardiovascular risks, unknown long-term effects - against uncertain benefits. Acknowledges that the risk-benefit calculus may not favor intervention when benefits are uncertain and harms are permanent.

GAC Model: Often minimises or omits discussion of harms. Frames decisions as “life-saving” without robust evidence. May present fertility preservation as adequate mitigation without discussing loss of sexual function, orgasmic capacity, or relationship implications. The “suicidality” framing distorts risk-benefit analysis by overstating benefits (suicide prevention) and understating significant, permanent harms.

Evidence: Clinic materials frequently emphasise mental health benefits while providing minimal information about physical harms. The framing “gender-affirming care saves lives” implies a benefit that systematic reviews have not established, while downplaying harms that are well-documented (sterility, bone density loss, surgical complications).

Compliance Assessment: Non-compliant. The GAC model’s framing distorts the risk-benefit calculus by overstating benefits and understating or omitting significant harms.

Capacity of Young People (Sections 4.6.2-3)

Code requirement: Ensure consideration of young people’s capacity for decision-making and consent. The Code requires heightened duties regarding best interests of the child, capacity assessment, parental involvement, and multidisciplinary input.

Standard Medical Model: recognises developmental limitations on capacity. Treats consent for permanent body modification as requiring mature understanding of long-term consequences, including abstract concepts like lifelong sterility, loss of sexual function, and permanent bodily changes.

GAC Model: May apply “affirmative” approach that privileges adolescent self-identification over developmental capacity concerns. The speed of assessment and intervention can fail to adequately test whether a young person truly comprehends irreversible consequences.

Evidence: Can a 14-year-old truly comprehend lifelong sterility? Can they understand what it means to never experience orgasm? Can they grasp that the body they’re modifying is the only one they’ll ever have? These are not rhetorical questions - they are capacity questions the Code requires doctors to address. The GAC model’s affirmative stance may insufficiently test this capacity.

Compliance Assessment: Non-compliant. The Code requires consideration of “young people’s capacity for decision-making and consent.” The GAC model’s affirmative stance may insufficiently test this capacity for permanent, life-altering interventions.

Honesty and Trustworthiness (Section 2.1)

Code requirement: Doctors must be honest, ethical and trustworthy.

Standard Medical Model: Honest about evidence limitations and uncertainty. Does not claim interventions are “medically necessary” or “life-saving” without robust evidence to support such claims.

GAC Model: May misrepresent evidence certainty. May claim interventions are “life-saving” or “medically necessary” without robust evidence. May mischaracterise psycho-therapeutic exploration as “conversion therapy,” foreclosing legitimate clinical approaches.

Evidence: The characterisation of psychological exploration of gender distress as “conversion therapy” is particularly problematic. Standard medical practice includes exploring underlying psychological factors (trauma, autism, same-sex attraction, mental health comorbidities) before recommending permanent interventions. Reframing this as “conversion therapy” is both inaccurate and forecloses appropriate clinical care.

Compliance Assessment: Non-compliant. Misrepresenting evidence quality or the necessity of interventions violates the fundamental requirement of honesty.

Disclosure of Professional Disagreement (Section 3.2.8)

Code requirement: Inform your patient when your personal opinion (in the context of practice) does not align with the profession’s generally held views.

Standard Medical Model: Aligns with evidence-based mainstream medical consensus as reflected in systematic reviews. Where uncertainty exists, acknowledges it.

GAC Model: Presents gender affirmation as settled medical consensus without disclosing: significant professional disagreement, systematic reviews questioning the evidence base, concerns raised by the Cass Review, multiple international evidence reviews reaching uncertain conclusions, and professional bodies in multiple countries restricting access based on evidence concerns.

Evidence: Sweden, Finland, the UK, and Norway have all restricted access to gender medical interventions for minors based on evidence reviews reaching similar conclusions to Cass. This represents significant international professional disagreement. GAC practitioners in Australia rarely disclose this to patients.

Compliance Assessment: Non-compliant. GAC practitioners often present their approach as uncontroversial medical consensus while failing to disclose substantial professional disagreement and evidence uncertainty.

Honest Medical Reports (Sections 10.9.1-2)

Code requirement: Be honest and not misleading in medical reports and certificates; take reasonable steps to verify content.

Standard Medical Model: Letters and reports accurately reflect evidence base and uncertainty. Do not overstate certainty or present contested claims as established fact.

GAC Model: Letters to surgeons or for legal purposes (e.g., birth certificate changes) may overstate evidence certainty, omit uncertainty, and present affirmation as medically necessary without acknowledging the contested evidence base.

Evidence: Medical letters supporting surgical referrals often state that surgery is “medically necessary” without qualifying this claim with evidence uncertainty. Letters supporting legal sex changes may assert that the person “is” the opposite sex without acknowledging this represents a contested philosophical position rather than medical fact.

Compliance Assessment: Non-compliant. Medical letters supporting legal sex changes or surgical referrals that misrepresent evidence certainty violate requirements for honesty in professional documents.

Adverse Event Monitoring (Sections 8.2.3-4)

Code requirement: Participate in systems of quality assurance; participate in surveillance and monitoring of adverse events.

Standard Medical Model: Maintains systematic follow-up; tracks outcomes including regret, detransition, complications; contributes data to evidence base.

GAC Model: Often inadequate long-term follow-up. May lose contact with patients. Limited systematic outcome tracking. Adverse events (detransition, regret, complications) may not be systematically recorded or reported.

Evidence: The evidence gap documented in systematic reviews exists in part because clinics have not maintained adequate long-term follow-up. The Cass Review noted the absence of reliable long-term outcome data. This is not merely a research failure - it’s a compliance failure. The Code requires participation in adverse event monitoring.

Compliance Assessment: Non-compliant. The lack of systematic outcome monitoring violates risk management obligations and contributes to the evidence gap that makes informed consent impossible.

Why the Standard Medical Model Complies

The Standard Medical Model demonstrates full compliance by:

• Requiring formal clinical assessment and diagnosis rather than relying solely on self-identification

• Providing comprehensive informed consent including evidence uncertainty, contested professional views, and full scope of permanent effects

• Exploring psychological and social factors underlying gender distress before recommending irreversible interventions

• Recommending interventions only when evidence supports reasonable expectation of efficacy

• Maintaining professional honesty about evidence limitations and contested claims

• Discussing all reasonable alternatives including psychological support and watchful waiting

• Ensuring systematic outcome monitoring, adverse event reporting, and contribution to evidence base

• Adequately weighing known harms against uncertain benefits

This is not a high bar. It is simply standard medical practice applied to a new clinical population.

The question is not whether the Standard Medical Model is perfect - no clinical approach is. The question is whether it meets the standards the Medical Board requires. It does.

Regulatory Implications

These compliance failures have serious consequences:

Patient Safety: Vulnerable young people are being exposed to permanent, irreversible interventions without adequate evidence of benefit and without full understanding of risks. This is not theoretical harm - it is young people sterilised, sexually incapacitated, and medically dependent for life based on decisions made when they were 14, 15, 16 years old, without adequate information or capacity to consent.

Informed Consent: Consent obtained without full disclosure of evidence uncertainty and contested professional views may not meet legal and ethical standards. This exposes practitioners to legal risk and, more importantly, fails patients who deserved better.

Professional Standards: Systematic deviation from Code requirements undermines public trust in medical regulation. If AHPRA does not enforce its own Code, what is the Code for?

Vulnerable Populations: Young people and their families are particularly vulnerable to exploitation through unsubstantiated claims. They trust doctors. They believe medical authority. When that trust is exploited through misleading claims about suicide prevention or medical necessity, the harm is profound.

Evidence Base: The failure to maintain systematic outcome monitoring perpetuates the evidence gap. Clinics prescribe interventions, lose contact with patients, and never know whether they helped or harmed. This is not merely poor practice - it violates explicit Code requirements for adverse event monitoring and quality assurance.

What AHPRA Should Do

The Australian Health Practitioner Regulation Agency and the Medical Board should:

1. Issue clear guidance that gender-related medical interventions must comply with standard Code requirements, particularly:

• Section 3.2.7 (reasonable expectation of clinical efficacy)

• Section 4.5 (informed consent including evidence uncertainty)

• Section 10.7.3 (not exploiting vulnerability through unsubstantiated claims)

2. Require informed consent processes that explicitly disclose:

• Evidence quality and uncertainty as documented in systematic reviews

• Contested nature of evidence base and professional disagreement

• Alternative approaches including psycho-therapeutic options

• Full scope of permanent effects including sexual function (not just fertility)

• Unknown long-term outcomes

• Lifelong medical dependency

3. Prohibit misleading claims about suicide prevention, medical necessity, or guaranteed outcomes in the absence of robust supporting evidence. The “transition or suicide” framing should be explicitly addressed as a form of exploitation prohibited by Section 10.7.3.

4. Mandate systematic outcome tracking including regret, detransition, and long-term complications as part of risk management obligations under Sections 8.2.3-4. Clinics should not be permitted to prescribe life-altering interventions without maintaining systematic follow-up.

5. Clarify that psychological exploration of factors underlying gender distress - including trauma, autism, same-sex attraction, mental health comorbidities - is standard medical practice, not “conversion therapy.” The mischaracterisation of appropriate clinical assessment as “conversion therapy” must be addressed.

6. Conduct targeted compliance audits of practices providing gender-related interventions, with particular attention to informed consent processes, disclosure of evidence uncertainty, and outcome monitoring systems.

Conclusion

The evidence is clear: the Gender Affirming Care model, as currently practised in Australia, demonstrates systematic non-compliance with the Medical Board’s Good Medical Practice Code across at least ten distinct areas, including two serious violations regarding treatment efficacy and exploitation of vulnerability.

The Standard Medical Model - which bases treatment recommendations on best available evidence, provides comprehensive informed consent, and maintains appropriate professional standards - is fully compliant.

This is not about ideology. It is not about whether gender dysphoria is “real” or whether some adults benefit from medical transition. It is about whether vulnerable young people and their families receive the same evidence-based, ethically sound medical care required in all other areas of medicine.

Would we accept a cancer treatment recommended without evidence of efficacy? Would we accept a cardiologist exploiting patients’ fear of heart attacks to sell unproven interventions? Would we accept surgical removal of healthy organs based on self-diagnosis with no formal assessment?

We would not. And we should not accept it here.

AHPRA and the Medical Board have a responsibility to ensure compliance with the Code. The Code exists for a reason. It protects patients. It maintains professional standards. It ensures that medical practice is based on evidence, not ideology.

It should apply to everyone.

Download - Executive Summary: Compliance Assessment: Gender Affirming Care Model vs Standard Medical Model - Submission to AHPRA and the Medical Board of Australia 20 May 2026

Simplified overview of the Standard Medical Model and the Gender Affirming Care model.

Please see https://www.aww.org.au/informed-consent for further information.

We’ve built policies around it. We’ve tested it with principals navigating contested situations. We’ve refined the language with parents who needed tools to push back on ideologically-driven school directives.

After our recent articles introducing the concept, the most common question has been: “But what does this actually look like in practice?“

So here’ is a couple of pages from one of our booklets: Social Transitioning – Risks & Harms showing how Parallel Dignity resolves tensions that DEI approaches have only escalated. In our next article we show how that framework can be applied to one of the most contested areas in education policy: supporting students distressed about their gender and body.

GUIDING PRINCIPLE: PARALLEL DIGNITY

Parallel Dignity is the principle that every human being possesses equal and inherent worth — not because of identity, belief, or circumstance, but by virtue of being human. It affirms that rights and recognition must never come at the expense of others’ safety, privacy, or truth.

WHY THIS MATTERS

Over the past decade, many school policies have been framed through Diversity, Equity and Inclusion (DEI) initiatives that, while well-intentioned, have often relied on identity categories rather than individual need.

• When diversity is defined as agreement with a single belief system, true diversity disappears.

• When equity is pursued through ideology rather than evidence, trust erodes.

• When inclusion overrides privacy and parental partnership, children lose protection.

In real terms:

• When a 12-year-old girl is told she must use pronouns that deny biological sex or be labelled a bully, diversity has become conformity.

• When schools implement policies based on activist lobbying rather than evidence reviews like Cass, equity becomes ideology.

• When parents discover their child has been socially transitioned at school without their knowledge, inclusion has overridden safeguarding.
  
  Parallel dignity restores balance. It recognises that compassion and caution are not opposites, and that evidence-based policy is itself an act of care.

WHAT PARALLEL DIGNITY LOOKS LIKE IN SCHOOLS

THE ETHICAL FOUNDATION FOR POLICY

Parallel dignity gives schools a rational moral framework to navigate conflict between rights, beliefs, and safety. It ensures that:

• Every child’s dignity is upheld in parallel, not ranked by ideology.

• Parents remain partners, not bystanders.

• Truth and kindness coexist in policy and practice.

• Safeguarding replaces signalling as the measure of inclusion.

By grounding decisions in this principle, educators can act with both compassion and clarity — supporting every student without compromising anyone’s rights.

[End Booklet Quotes ]

A Key point of Parallel Dignity:

From Identity Categories to Needs-Based Equity

On of the key points we reiterate in our materials is that public resources and protections should be distributed based on demonstrable need, not assumed disadvantage tied to identity categories such as race, gender identity, or sexual orientation.

Parallel dignity recognises the unique experiences of individuals and communities, but rejects stereotyping—whether for exclusion or special treatment. It upholds that:

• Fairness requires measurable criteria such as poverty, trauma, disability, or housing insecurity—not proxies like race or sexuality.

• All children deserve support when they are vulnerable, regardless of their identity background.

• Policies based on need, not narrative, build trust and cohesion—avoiding both tokenism and neglect.

To preserve both equality and dignity, we must move from broad identity-based allocations to targeted, inclusive support systems grounded in evidence, transparency, and shared humanity.

• Identity categories can be meaningful when lived experience is directly relevant.

• But dignity requires us not to stereotype groups—whether for pity or for blame.

• Justice demands needs-based assessment, not politically convenient categories.

See next:
Parallel Dignity in Practice: Supporting Gender-Distressed Students (part 4)
Catherine Karena

From those discussions, the concept of Parallel Dignity began to take shape.

We humans are really good at coming up with reasons for not liking each other and for wanting to dominate the people in the next village. But if we’re all spread out in the middle of nowhere, it often doesn’t matter - we just keep our distance from “those bastards over there.” Different groups, all with differing beliefs, rules, and rights, simply mind their own business and do their own thing. In the middle of nowhere, the strategy of “keep our distance” can work quite well. It’s a similar strategy to the one we use for sharks, crocodiles, and anything else it’s wise to avoid.

However, in environments where different types of people interact through necessity - like in a crowded train or a workplace - harmony can only be achieved when a clash of rules or rights is resolved not with one side “winning,” but with both sides finding accommodation. We need to reach a point where both sides are treated with dignity. We refer to this as Parallel Dignity: creating an environment in which both types of individuals can enjoy respect and protection without encroaching on each other’s rights.

Well-accepted examples demonstrating Parallel Dignity include:

• Silent train carriages where mobile phone conversations are not permitted

• Designated areas for smokers and non-smokers

• Spaces, sports, and services separated by sex

Ah, yes, that third one - spaces, sports, and services separated by sex - a once obvious separation no longer accepted at all by certain people, leading to a clash of rights. But on this very subject, a path to Parallel Dignity has been proposed by leading members of the transsexual community. You can click here to read their Declaration, but it’s worth taking a moment right now to glance at its well-articulated conclusion:

“Beyond our male or female bodies, each of us is a unique tapestry of identity - woven with threads of race, ethnicity, religion, nationality, class, family history, abilities, and life experiences. We all deserve the freedom to express our full humanity beyond the constraints of stereotypes or prescribed ‘gender identities.’ Our shared humanity calls us to rise above divisive labels, embracing each person’s dignity and individuality.”

Parallel Dignity is a key part of a sophisticated social etiquette that, while enabling friendly and productive interaction, also acknowledges individual needs around personal boundaries and consent.

But here’s the problem: there seems to be a bunch of people out there whose purpose in life is to sow hate and division, subvert cultural norms, and derail society. Cultivating Parallel Dignity is definitely not on their agenda. So let’s dig a bit deeper into ideas around dignity, rights, the cultural moment in which we find ourselves, and the obstacles blocking our path to Parallel Dignity.

The Enemies of Parallel Dignity

What’s Wrong with Rights?

For many humans, their default approach to others is adversarial: “I’m right and you’re wrong. Do it my way... or else.” When groups adopt this win-at-all-costs way of interacting with each other, they form competing tribes, and we get an “us and them” culture often leading to endless animosity and conflict. Any suggestion of those “lesser beings” outside the tribe having any “rights” or “dignity” would be greeted with derision.

This adversarial approach toward others is the very opposite of a worldview based on human dignity. And that’s where the concept of “rights” comes in.

When the Universal Declaration of Human Rights appeared in 1948, the goal was to enable different types of people to “get along” - to enable diverse groups to interact in ways that nurtured human flourishing, freedom, and justice. The idea was that these rights reflected widely shared values about the way people should be treated and what people should be able to freely do in order to survive and thrive.

But with rights also comes responsibility - first and foremost, a shared responsibility to respect the rights of others. And a problem arises when some people happily accept the rights but not the responsibility that goes with them.

The human rights relating to diverse groups cannot be absolute, because often those rights clash. For example, when the Taliban shot Malala, they could claim they were pursuing their right to freedom of religion, whereas Malala could say she was pursuing a girl’s right to education. Rights clash.

Other problems around the notion of human rights occur when the concept is corrupted - for example, when “demands” are framed as “rights,” or when certain rights are not even grounded in reality. An example that fits both categories is “trans rights are human rights.” Why? Because some of these “rights” are no more than “demands,” and “trans” refers to people who believe they are the opposite sex, which is not biologically possible.

But What Is This Thing Called Dignity?

For humans, dignity is the big prize - the gold standard one hopes for as one moves through life and society. From the way we enter this world to the way we leave it, we want there to be a sense of dignity. And the most dignified thing of all is to want it for others as well.

Human dignity sees each person as a free being with a unique history. It centers on the right of a person to be valued and respected for their own sake. And it’s a concept that underpins the idea that all individuals should be treated with decency, fairness, and without discrimination.

Human Rights vs Human Dignity

The Universal Declaration of Human Rights states: “All human beings are born free and equal in dignity and rights... and should act towards one another in a spirit of brotherhood.”

So, as we can see, dignity and rights appear together, and building on those as a foundation, the idea was to encourage a sense of unity, cooperation, and shared responsibility. It’s easy to see that the original Declaration and the concept of Parallel Dignity are a good fit.

But all these decades later, we can see there’s been a warping of the Declaration’s intention. Put bluntly, society seems increasingly strewn with individuals and groups who jump up and down about MY RIGHTS but who don’t give a damn about YOUR RIGHTS or YOUR DIGNITY. Society can only function smoothly when rights are paired with dignity, and when both are paired with responsibility: “When you pick up one end of the stick, you pick up the other.”

In the West, a major force affecting human dignity is what is often called identity politics. So, in order to understand how we may get around this “obstacle,” let’s explore the essence of that as well.

Our Current Cultural Moment

Whatever we call it - identity politics, Wokeism, or Critical Social Justice - this modern movement is, at its core, the “making sacred” of historically marginalised or oppressed identity groups. It makes such groups “special” - with “special” knowledge, “special” lived experience, and a “special” understanding of what are, apparently, countless systemic “isms” and “phobias” that continue to hold them back, all made a thousand times worse by the somewhat vague notion of “inter-generational trauma.” We are then led to believe that this grab-bag of historical disadvantages gives such groups a “special” moral authority to which the rest of society must defer.

Getting a fairly large slice of “the rest of society” to defer to a sacred caste has proven relatively easy. By using emotional blackmail based on shame and guilt, those in society deemed to belong to historical “oppressor” groups can readily be convinced that they must atone for their many “sins” - and the sins of their fathers - by being stripped of any moral standing and, while we’re at it, also being stripped of their dignity. (To put it another way, if your particular identity places you on the “wrong side of history,” then your dignity doesn’t count because, well, it’s something to do with retribution.)

Identity politics is awash with: “My rights are human rights. And if I belong to one of the sacred castes and you don’t, then my rights trump your rights.” This creates a messy and unworkable hierarchy of rights, demands, grievances, and victimhood. This in turn leads to a paradoxical situation which is both a “race to the top” and a “race to the bottom” - the Oppression Olympics - where the more “oppression points” I can pick up by racing to the bottom, the sooner I can claim my “special” status and then start my race to the top.

This divisive, adversarial approach to life and relationships is totally at odds with the notion of individual human dignity and, by extension, the universal embrace of Parallel Dignity. So, while much of the western world is still ruled by the Woke Industrial Complex, what hope is there for a wider acceptance of Parallel Dignity as a cultural tool which helps diverse groups coexist in a way that is genuinely welcoming and productive?

The Growing Thirst for Parallel Dignity

Somewhere beyond the land of the “Primitive Adversarial” and somewhere also beyond the land of “21st Century Woke” is a higher place that maybe, just maybe, is a tad happier and healthier. It’s not “heaven” and it’s not “utopia,” but it’s got to be better than - just to pluck an example out of the ether - state-sanctioned predation upon troubled autistic teenage girls.

We can’t fully describe that “higher place” yet, but one thing we know for sure is that concepts like Parallel Dignity will be very much at home there. The reason we can’t fully describe this higher place is because it hasn’t been built. And the only ones who can build it are us. Which begs the question: who is “us”?

The people who will build a better society - one centered on Parallel Dignity - are folk whose actions and intentions are grounded in reality and reason and who have the skill and the wisdom to envision that higher place and then create it.

As the world gradually turns away from woke - and it will - there’s an opportunity for wise and rational leaders to reclaim the true meaning and intention of the ideas around human rights and human dignity. Those leaders will also take ownership of terms like Parallel Dignity and promote the aspirational state it represents.

Whether the seemingly intractable issue at hand concerns sex or class or ethnicity or the impact of colonization, getting buy-in for high-level concepts like Parallel Dignity will be the mark of leaders who can truly bring people together.

Exactly what that set of leaders looks like is not known because, like the higher place itself, it’s yet to be assembled.

However, maybe, just maybe, one of them is you.

The invitation is open.

Graeme Bowman,

POSTSCRIPT:
It was hard thinking of what image to make to go with Graeme’s piece. I chose to have this created. We’ve all seen this image used on the left to explain “equity.” Three people trying to see a baseball game they hadn’t paid a ticket for. I look at that and I can see the ‘why’ of DEI Hire. It assumes access should be allocated by identity rather than earned.

That creates a system where outcomes are adjusted, but fairness becomes harder to define. There’s another way. In AWW, Parallel Dignity starts from a different premise: every person has equal inherent worth - without ranking or prioritising groups.

Where someone is genuinely struggling, that matters. But the help should follow the need - not be assumed from the colour of their skin, their sex, or what group they belong to. Because when we assume disadvantage from identity, we erase the individual. And erasing the individual is never dignity - whatever name we give it

Where disadvantage exists, address it based on actual need, not identity categories.

The goal isn’t to stand on boxes. It’s to ensure everyone has a genuine path to a seat in the stadium.

​Teachers and principals trusted that advice.

​But new international reviews and court decisions have changed the landscape. Evidence now shows that social transition is not a neutral act and may place children on a pathway toward irreversible medical interventions.

​This booklet was created to help school leaders navigate that turning point. Drawing on the Cass Review, the Australian Re: Devin case, and global policy reforms, it explains the risks, legal responsibilities, and ethical considerations schools must now understand.

​Most importantly, it offers a practical framework — Parallel Dignity — that allows schools to support every child while protecting truth, safety, privacy, and parental partnership. Parallel Dignity is a framework we have been working on for 18 months now:

If you work in education, this guide will help you understand what has changed — and what responsible safeguarding now requires.

DOWNLOAD - Social Transitioning - The Risks & Harms (New Zealand)

DOWNLOAD - Social Transitioning - The Risks & Harms (Australia)

Now! We fully know that the one of the major reasons teachers feel obliged to rush children into social transitioning - is because of hearing statements like this:

”Half of trans youth will attempt suicide without immediate medical treatment.”

​You’ve heard this claim. But is it true?

​This evidence review answers the critical questions policymakers and families are asking:

• Where do the alarming suicide statistics come from?

• Do puberty blockers and hormones actually prevent suicide?

• What does high-quality research show about suicide risk?

• What does good mental health care look like?

The findings may surprise you. Deaths by suicide among gender-distressed youth are rare. Medical interventions show no proven mental health benefit. And the most frequently cited statistics come from self-selected online surveys—not population data.

We’ve produced a simple, clear booklet with evidence every parliamentarian, clinician, teacher and parent should see before making irreversible decisions about young people’s care.

DOWNLOAD - Suicide Risk And Gender Distressed Youth

DOWNLOAD - Quick Reference Guide for Policy Makers

All updates can be found here: https://www.aww.org.au/suicide

Please consider supporting our work with either subscription or donation. We work full-time with no support. The protection of children from medical and body modification on minors, is not something the government supports.